

State Fiscal Year 2021 Supplemental Rebate Agreement Reporting

February 1, 2022



*Division of Health Care Financing & Policy
Nevada Medicaid
Nevada Department of Health and Human Services*

Suzanne Bierman, JD MPH
*Administrator
Division of Healthcare Financing & Policy*

Steve Sisolak
*Governor
State of Nevada*

Richard Whitley, MS
*Director
Department of Health and Human Services*

State Fiscal Year 2021 Supplemental Rebate Agreement Reporting

Nevada Revised Statutes Chapter 422.4025, Section 6 requires reporting concerning the financial effects

In Nevada, three managed care organizations enter into rebate agreements to purchase prescription drugs for health plans under the Medicaid program. A pharmacy benefit manager enters into rebate agreements on behalf of the fee-for-service Medicaid program. A summary of these agreements is provided in Table 1 below.

Table 1

Summary of Supplemental Rebate Agreements for Health Plans in SFY2021			
Health Plan	Number of Unique Manufacturers Under Contract	Total Supplemental Rebates Invoiced	Total Supplemental Rebates Collected
Anthem	188	\$4,356,799.27	\$3,917,466.84
Health Plan of Nevada	46	\$9,900,008.26	\$9,699,600.20
SilverSummit Healthplan	188	\$1,036,758.98	\$952,656.32
Totals for Managed Care Health Plans	-	\$15,293,566.51	\$14,569,723.36
Fee-for-Service Medicaid	37	\$9,899,735.91	\$9,880,956.16
Totals	-	\$25,193,302.42	\$24,450,679.52

Each of these managed care organizations has provided additional information specific to their health plan’s supplemental rebate agreements in the following order:

- Anthem (pages 2 - 18)
- Health Plan of Nevada (pages 19 - 24)
- SilverSummit Healthplan (pages 25 - 40)

Please note, Health Plan of Nevada, due to plan concerns regarding the confidentiality of rebate data, was the only organization not to identify the manufacturer names in Table 3 (see pages 23 - 24) which reports the amount invoiced and collected from supplemental drug rebates. Health Plan of Nevada felt that disclosure would have an adverse effect on their pharmacy benefit manager’s ability to negotiate effectively in the future with manufacturers.

Additional information specific to supplemental rebate agreements related to prescription drugs for fee-for-service Medicaid recipients is provided by a pharmacy benefit manager vendor (OptumRx):

- Fee-for-Service Medicaid (pages 41 - 47)

Please refer to the individual reports within this document for more information.

**Anthem Blue Cross and Blue Shield Healthcare Solutions
Supplemental Rebate Agreement Report
State Fiscal Year 2021 (July 1, 2020 to June 30, 2021)**

The overall drug rebate process follows the Omnibus Budget Reconciliation Act of 1990 (OBRA '90) as codified in Section 1927 of the Social Security Act (42 U.S.C. 1396r-8) and regulations promulgated by the Centers for Medicare & Medicaid Services (CMS). Under the Medicaid drug rebate program (MDRP), drug manufacturers must provide rebates to the federal government and states as a condition of having their drugs covered by Medicaid. The MDRP helps lower Medicaid prescription drug spending by ensuring that state Medicaid agencies receive discounts in the form of rebates on covered outpatient drugs. In order for their covered outpatient drugs to be covered and reimbursed by state Medicaid agencies, pharmaceutical manufacturers must enter into and have in effect the National Drug Rebate Agreement (NDRA) with the Secretary of the United States Department of Health and Human Services (HHS). The NDRA provides for the payment of Federal rebates by pharmaceutical manufacturers. Nevada Medicaid and the other state Medicaid Programs are third party beneficiaries of the NDRAs. The formulas for calculating the Federal unit rebate amount (URA) are set out by Federal statute.

States may also directly negotiate with manufacturers for voluntary supplemental rebates on top of federally required rebates. States may enter separate or supplemental drug rebate agreements as long as such agreements achieve drug rebates equal to or greater than the drug rebates set forth in the Secretary's national rebate agreement with drug manufacturers, which is published at 56 F.R. 7049 (1991).

The supplemental rebate does not reduce what is being paid under the NDRA but instead, provides an additional tool for states to help manage prescription drug spend. Pharmaceutical manufacturers enter into supplemental rebate agreements (SRA) with state Medicaid agencies to ensure preferred status on the states' Preferred Drug Lists.

The Nevada Medicaid Supplemental Drug Rebate Program (NMSDRP) has been in effect since January 1, 2012. The SRAs are between the manufacturers and the Nevada Department of Health and Human Services, Division of Health Care Financing and Policy (DHCFP). Generally, the SRAs are in effect for one calendar year beginning on January 1st and terminating on December 31st. In some instances, the SRA can have an alternative start date as a result of either newly contracted drugs or new NDCs (National Drug Codes) released for drugs currently under contract. Additionally, there are factors that may cause a contract to have a non-December 31st end date such as a product moving to non-preferred status or to coincide with planned Silver State Scripts Board (SSSB) review.

During State Fiscal Year 2021, the rebates negotiated under the NMSDRP only applied to Medicaid fee-for-service (FFS) utilization. The other entities, authorized under SB378 to participate in the Medicaid FFS PDL, did not elect to participate.

Supplemental rebates are calculated based upon two different types of calculations at the unit level:

- “Percentage of WAC” - set percentage of the drug’s published wholesale acquisition cost (WAC).
- “GNUP” (Guaranteed Net Unit Price) - WAC minus the Federal URA minus the GNUP.
 - In the event a drug’s WAC minus the Federal URA is lower than the GNUP, the supplemental rebate rate is zero.
 - Even though there are instances when the GNUP contract does not produce supplemental rebate savings, they remain in place to give Nevada Medicaid price protection in case the manufacturer raises the drug price during the contract term.

Anthem Blue Cross and Blue Shield Healthcare Solutions is the trade name of Community Care Health Plan of Nevada, Inc., an independent licensee of the Blue Cross and Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.

The type of calculation used for a particular product is defined within a manufacturer’s SRA with Anthem Blue Cross and Blue Shield Healthcare Solutions.

Section F of the SRA provides confidentiality assurance that the State and the manufacturer agree to maintain confidentiality and to not disclose pricing information or pricing related terms and conditions.

Anthem Blue Cross and Blue Shield Healthcare Solutions had 196 SRAs in place that were in effect during a portion of State Fiscal Year 2021 (July 1, 2020 – June 30, 2021) (hereinafter referred to as SFY 2021). Table 1 below summarizes the agreements:

Table 1 Row Definitions:

- Number of Contracts - The count of signed SRAs that were in force during some period within SFY 2021.
- Number of Unique Manufacturers Under Contract - The count of unique manufacturers with a signed SRA in force during some period within SFY 2021.
- Amount Plan Paid for Products During Contract Term - The amount Anthem Blue Cross and Blue Shield Healthcare Solutions paid for all drugs subject to a manufacturer’s SRA during SFY 2021.

- Example: Drug “A” was subject to an SRA from 01/01/2020 to 12/31/2020 but not under an agreement in 2021. This column would include the amount Anthem Blue Cross and Blue Shield Healthcare Solutions paid for Drug “A” for claims paid from 07/01/2020 to 12/31/2020.
- Amount Plan Paid to Pharmacies/Providers for Products Under Contract - The amount Anthem Blue Cross and Blue Shield Healthcare Solutions paid to pharmacies and providers for drugs subject to a manufacturer’s SRA during SFY 2021.
- Total Supplemental Rebates Invoiced - The supplemental rebate amount invoiced during SFY 2021 to manufacturers for drugs subject to SRAs.
- Total Supplemental Rebates Collected - The supplemental rebate amount collected during SFY 2021 to manufacturers for drugs subject to SRAs.
- Supplemental Rebate Percentage of Drug Spend for Contracted Products - The result of dividing the contract value by the drug spend for contracted drugs, expressed as a percentage.

Table 1

Summary of Supplemental Rebate Agreements in Place during SFY 2021	
Number of Contracts	196
Number of Unique Manufacturers Under Contract	188
Amount Plan Paid for Products During Contract Term	\$124,412,739.35
Amount Plan Paid to Pharmacies/Providers for Products Under Contract During Contract Term	\$117,567,093.68
Total Supplemental Rebates Invoiced	\$4,356,799.27
Total Supplemental Rebates Collected	\$3,917,466.84
Supplemental Rebate Percentage of the Total the Plan Paid for Contracted Products	3.50%

Table 2 below lists the SRAs in place during SFY 2021. The list is sorted alphabetically by manufacturer name and by SRA start dates.

Table 2 Column Definitions:

- Manufacturer Name - The name of the entity the State has contracted with in the SRA.
- Contract Term - The effective and termination dates of the SRA.

Table 2

Supplemental Rebate Agreements in Place during SFY 2021	
Manufacturer Name	Contract Term
60 DEGREES	01/01/2020 - 12/31/9999
ABBOTT DIABETES CARE	01/01/2020 - 12/31/2022
ABBVIE INC	01/01/2017 - 12/31/9999
ACERUS	04/01/2021 - 12/31/9999
ACLARIS	10/01/2019 - 09/30/2020
ACORDA THERAPEUTICS INC	01/01/2020 - 12/31/2023
AERIE	01/01/2020 - 12/31/9999
AKARX Inc	09/01/2020 - 12/31/9999
AKEBIA THERAPEUTICS INC	01/01/2020 - 12/31/9999
AKORN, INC	01/01/2020 - 12/31/2022
ALEXION PHARMACEUTICALS INC	01/01/2020 - 12/31/9999
ALFASIGMA USA	01/01/2020 - 12/31/9999
ALK ABELLO INC	01/01/2020 - 12/31/9999
ALKERMES INC	04/01/2020 - 12/31/2025
ALLEGIS	04/01/2017 - 12/31/9999
ALLERGAN PHARM	01/01/2020 - 12/31/9999
ALMATICA	10/01/2020 - 12/31/9999
AMAG PHARMACEUTICALS, INC	01/01/2020 - 12/31/9999
AMARIN	01/01/2020 - 12/31/9999
AMGEN	01/01/2020 - 12/31/2022
AMNEAL PHARMACEUTICALS LLC	01/01/2020 - 12/31/9999
ANTARES PHARMA INC	01/01/2020 - 12/31/9999
AQUA PHARMACEUTICALS	01/01/2020 - 03/31/2022
ARBOR	01/01/2020 - 12/31/2021
ARKRAY USA INC	01/01/2020 - 12/31/2022
ASCEND THERAPEUTICS US, LLC	01/01/2020 - 03/31/2022
ASEGUA	01/01/2020 - 12/31/9999
ASSERTIO	01/01/2020 - 12/31/9999
ASTELLAS PHARMA US	01/01/2020 - 12/31/9999
ASTRA ZENECA	01/01/2020 - 12/31/9999
AVANIR PHARMACEUTICALS	01/01/2020 - 12/31/2023
AVEXIS	07/01/2019 - 12/31/2022
AVION PHARMACEUTICALS	01/01/2020 - 12/31/9999
BANNER LIFE SCIENCES	10/01/2020 - 12/31/2023
BAYER	01/01/2020 - 12/31/2022
BAYER DIAGNOSTICS	01/01/2020 - 12/31/9999
BECTON DICKINSON	01/01/2020 - 12/31/9999
BIODELIVERY SCIENCES INT	07/01/2019 - 12/31/9999
BIOGEN	01/01/2020 - 12/31/9999

Supplemental Rebate Agreements in Place during SFY 2021	
Manufacturer Name	Contract Term
BIOHAVEN PHARMACEUTICALS	04/01/2020 - 12/31/2022
BIOVENTUS LLC	01/01/2020 - 12/31/9999
BOEHRINGER INGELHEIM	01/01/2020 - 12/31/9999
BRISTOL-MYERS SQUIBB	01/01/2020 - 12/31/9999
CELGENE CORP	01/01/2020 - 12/31/2020
CELLTRION	10/01/2019 - 12/31/2022
CEQUR CORPORATION	01/01/2021 - 12/31/9999
CHIESI USA	01/01/2020 - 12/31/9999
CLOVIS ONCOLOGY INC	01/01/2020 - 12/31/2022
COHERUS BIOSCIENCES	01/01/2020 - 12/31/9999
COLLEGIUM PHARMACEUTICALS	07/01/2019 - 12/31/9999
COVIS PHARMA	01/01/2020 - 12/31/9999
CROWN LABORATORIES	01/01/2020 - 12/31/2022
CSL BEHRING LLC	01/01/2020 - 12/31/9999
CUMBERLAND PHARMACEUTICALS	01/01/2020 - 12/31/9999
CURRAX PHARMACEUTICALS LLC	01/01/2020 - 12/31/9999
CUTANEA LIFE SCIENCES INC	01/01/2020 - 12/31/9999
CYCLE PHARMACEUTICALS	01/01/2020 - 12/31/9999
DERMIRA, INC	01/01/2020 - 12/31/9999
DEXCOM	01/01/2020 - 12/31/9999
DIGESTIVE CARE	01/01/2020 - 12/31/9999
DUCHESNAY USA, INC	01/01/2020 - 08/31/2022
EGALET CORPORATION	01/01/2020 - 12/31/9999
EISAI INC	01/01/2020 - 12/31/9999
ELECTROCORE	01/01/2020 - 12/31/9999
ELI LILLY & COMPANY	01/01/2020 - 12/31/2022
EMD SERONO	01/01/2019 - 12/31/2021
EMERGENT DEVICES	01/01/2020 - 12/31/2020
EMERGENT DEVICES	01/01/2021 - 12/31/9999
ENCORE DERMATOLOGY, INC	01/01/2020 - 09/30/2021
ENDO PHARMACEUTICAL SOLUTIONS	10/01/2019 - 12/31/2023
EPI HEALTH LLC	01/01/2020 - 12/31/9999
ESPERION THERAPEUTICS	04/01/2020 - 12/31/2022
EXELIXIS INC	01/01/2020 - 12/31/2021
EXELTIS USA DERMATOLOGY	01/01/2020 - 12/31/9999
EYEVANCE	01/01/2020 - 12/31/2022
FERRING	01/01/2020 - 12/31/9999
FIDIA PHARMA USA INC	01/01/2020 - 12/31/9999
FORTOVIA THERAPEUTICS	01/01/2020 - 12/31/2022
FORWARD SCIENCE	01/01/2020 - 12/31/9999
FOUGERA PHARMACEUTICALS INC	01/01/2020 - 12/31/2021

Supplemental Rebate Agreements in Place during SFY 2021	
Manufacturer Name	Contract Term
FRESENIUS USA	01/01/2020 - 12/31/2021
GALDERMA	07/01/2007 - 12/31/2020
GALDERMA	01/01/2021 - 12/31/2023
GALEN	01/01/2020 - 02/28/2022
GENENTECH	01/01/2020 - 12/31/2022
GENESIS HEALTH TECHNOLOGIES	01/01/2020 - 12/31/9999
GILEAD SCIENCES INC	01/01/2020 - 12/31/9999
GLAXO SMITHKLINE	01/01/2019 - 12/31/2020
GLAXO SMITHKLINE	01/01/2021 - 12/31/9999
GLENMARK THERAPEUTICS INC	01/01/2020 - 12/31/9999
GREENWICH BIOSCIENCES	01/01/2020 - 12/31/2021
GREER LABORATORIES, INC	01/01/2020 - 12/31/9999
GRIFOLS USA, LLC	01/01/2020 - 12/31/2022
HELSINN THERAPEUTICS	01/01/2020 - 08/31/2021
HIKMA AMERICAS	01/01/2020 - 12/31/9999
HORIZON PHARMA USA, INC	01/01/2020 - 12/31/9999
HTL-STREFA	04/01/2021 - 12/31/9999
INDIVIOR	07/01/2019 - 12/31/9999
INSMED	07/01/2019 - 12/31/9999
INSULET	01/01/2020 - 12/31/9999
INSYS THERAPEUTICS, INC	01/01/2015 - 03/31/2021
IPSEN BIOPHARMACEUTICALS INC	01/01/2020 - 03/31/2022
IRONSHORE	01/01/2020 - 12/31/9999
IRONWOOD PHARMACEUTICALS INC	10/01/2017 - 07/31/2020
JAZZ	04/01/2020 - 12/31/2022
JOHNSON and JOHNSON	01/01/2017 - 12/31/2020
JOHNSON and JOHNSON	01/01/2021 - 08/31/2021
JOURNEY MEDICAL	09/01/2020 - 12/31/9999
KALA PHARMACEUTICALS INC	01/01/2020 - 12/31/9999
KOWA PHARMACEUTICALS	01/01/2020 - 12/31/9999
KYOWA KIRIN	01/01/2020 - 06/30/2022
LEO PHARMA, INC	01/01/2020 - 12/31/2022
LIFESCAN	01/01/2020 - 12/31/9999
LUPIN PHARMACEUTICALS, INC	07/01/2013 - 06/30/2021
MAGNA PHARMACEUTICALS	04/01/2017 - 09/30/2020
MALLINCKRODT	10/01/2019 - 12/31/9999
MANKIND CORPORATION	01/01/2020 - 12/31/9999
MAYNE PHARMA	01/01/2020 - 12/31/9999
MEDEXUS PHARMA	01/01/2020 - 12/31/2021
MELINTA THERAPEUTICS INC	01/01/2020 - 12/31/9999
MERCK & CO, INC	01/01/2020 - 12/31/9999

Supplemental Rebate Agreements in Place during SFY 2021	
Manufacturer Name	Contract Term
METUCHEN	01/01/2020 - 12/31/9999
MILLENNIUM PHARMACEUTICALS	01/01/2021 - 12/31/2023
MILLICENT	01/01/2020 - 06/30/2022
MINIMED DISTRIBUTION CORP	01/01/2020 - 12/31/9999
MISSION	01/01/2020 - 12/31/9999
MYLAN PHARMACEUTICALS INC	01/01/2020 - 12/31/2022
NABRIVA	01/01/2020 - 12/31/9999
NEOS THERAPEUTICS LP	01/01/2020 - 12/31/9999
NESTLE HEALTH SCIENCE	01/01/2020 - 12/31/2020
NESTLE HEALTH SCIENCE	01/01/2021 - 12/31/9999
NEURELIS	10/01/2020 - 12/31/9999
NEUROCRINE BIOSCIENCES INC	01/01/2020 - 12/31/9999
NODEN PHARMA USA	01/01/2020 - 12/31/9999
NOVARTIS	01/01/2020 - 12/31/9999
NOVEN THERAPEUTICS LLC	01/01/2020 - 12/31/9999
NOVO NORDISK	01/01/2020 - 12/31/2021
OPKO PHARMACEUTICALS LLC	01/01/2020 - 12/31/9999
OPTINOSE US, INC	01/01/2020 - 12/31/9999
OREXO	07/01/2019 - 12/31/2021
ORTHOGENRX	01/01/2020 - 11/12/2022
OTSUKA	01/01/2020 - 12/31/9999
PARATEK PHARMACEUTICALS, INC	01/01/2020 - 12/31/2022
PARI RESPIRATORY	01/01/2020 - 12/31/9999
PERRIGO	01/01/2020 - 12/31/9999
PFIZER US PHARM	01/01/2020 - 12/31/9999
PHARMING HEALTHCARE INC	01/01/2020 - 12/31/9999
PIERRE FABRE PHARMA INC	01/01/2020 - 12/31/9999
PURDUE PHARMA	10/01/2019 - 12/31/9999
RADIUS HEALTH INC	01/01/2020 - 12/31/9999
RECKITT BENCKISER	01/01/2020 - 12/31/9999
REDHILL BIOPHARMA	01/01/2020 - 12/31/2023
REGENERON PHARMACEUTICALS INC	10/01/2020 - 12/31/9999
RETROPHIN INC	01/01/2020 - 12/31/9999
RHODES PHARMACEUTICALS LP	01/01/2020 - 08/31/2021
ROCHE DIAGNOSTICS	01/01/2020 - 12/31/2022
SANDOZ INC	04/01/2020 - 12/31/9999
SANOFI - AVENTIS	07/01/2013 - 12/31/9999
SCILEX PHARMACEUTICALS INC	07/01/2019 - 12/31/9999
SEBELA PHARMACEUTICALS INC	01/01/2020 - 12/31/2020
SEBELA PHARMACEUTICALS INC	01/01/2021 - 12/31/9999
SECURA BIO	01/01/2021 - 12/31/9999

Supplemental Rebate Agreements in Place during SFY 2021	
Manufacturer Name	Contract Term
SHIONOGI & COMPANY, INC	01/01/2020 - 12/31/2023
SHIRE-RICHWOOD	08/01/2019 - 08/31/2021
SK LIFE SCIENCE	04/01/2020 - 12/31/9999
SOBI INC	01/01/2020 - 12/31/2021
SUN PHARMA INDUSTRIES INC	01/01/2020 - 12/31/2022
SUNOVION	01/01/2020 - 12/31/2022
SUPERNUS PHARMACEUTICALS, INC	01/01/2020 - 12/31/9999
SYNERGY	04/01/2020 - 12/31/9999
TAKEDA	10/01/2019 - 12/31/9999
TERSERA THERAPEUTICS	01/01/2020 - 12/31/9999
TESARO, INC	04/01/2016 - 09/30/2020
TEVA	01/01/2020 - 12/31/9999
TherapeuticsMD INC	01/01/2020 - 12/31/9999
TOLMAR PHARMACEUTICALS INC	07/01/2017 - 09/30/2020
TOLMAR PHARMACEUTICALS INC	10/01/2020 - 12/31/9999
TRIS PHARMA	01/01/2020 - 12/31/9999
TRIVIDIA HEALTH	01/01/2020 - 12/31/2022
UCB INC	01/01/2020 - 12/31/9999
UNITED THERAPEUTICS CORP	01/01/2015 - 06/30/2021
UPSHER-SMITH	01/01/2020 - 12/31/9999
US WORLDMEDS, LLC	01/01/2020 - 08/31/2021
VALEANT PHARMACEUTICALS	01/01/2020 - 12/31/9999
VELOXIS PHARMACEUTICALS	01/01/2020 - 12/31/9999
VERTICAL PHARMACEUTICALS	01/01/2020 - 12/31/9999
VIFOR PHARMA, INC	01/01/2020 - 12/31/2022
VIVUS	01/01/2020 - 12/31/9999
VYERA PHARMACEUTICALS	01/01/2020 - 12/31/9999
VYNE PHARMACEUTICALS INC	01/01/2021 - 12/31/2023
WOMENS CHOICE PHARMACEUTICALS	01/01/2020 - 12/31/9999
XERIS	03/01/2020 - 12/31/9999
XSANVITA, LLC	01/01/2014 - 12/31/9999
ZEALAND PHARMA US INC	01/01/2020 - 12/31/9999
ZIMMER US, INC	01/01/2020 - 12/31/2022

Table 3 below provides the values for supplemental rebates. Table 3 is sorted by Manufacturer Name.

Table 3 Column Definitions:

- Manufacturer Name - The name of the entity the State has contracted with in the SRA.
- Amount Plan Paid for Products During Contract Term - The amount Anthem Blue Cross and Blue Shield Healthcare Solutions paid for all drugs subject to a manufacturer's SRA during SFY 2021.
 - Example: Drug "A" was subject to an SRA from 01/01/2020 to 12/31/2020 but not under an agreement in 2021. This column would include the amount Anthem Blue Cross and Blue Shield Healthcare Solutions paid for Drug "A" for claims paid from 07/01/2020 to 12/31/2020.
- Amount Plan Paid to Pharmacies/Providers for Products Under Contract - The amount Anthem Blue Cross and Blue Shield Healthcare Solutions paid to pharmacies and providers for drugs subject to a manufacturer's SRA during SFY 2021.
- Total Supplemental Rebates Invoiced - The supplemental rebate amount invoiced during SFY 2021 to manufacturers for drugs subject to SRAs.
- Total Supplemental Rebates Collected - The supplemental rebate amount collected during SFY 2021 to manufacturers for drugs subject to SRAs.

Table 3

Supplemental Rebate Agreements in Place during SFY 2021				
Manufacturer Name	Amount Plan Paid for Products During Contract Term	Amount Plan Paid to Pharmacies/ Providers for Products Under Contract During Contract Term	Total Supplemental Rebates Invoiced	Total Supplemental Rebates Collected
60 DEGREES	\$0.00	\$0.00	\$0.00	\$0.00
ABBOTT DIABETES CARE	\$75,288.10	\$71,064.15	\$8,987.63	\$5,936.72
ABBVIE INC	\$12,589,149.38	\$12,549,101.31	\$767,851.42	\$760,789.64
ACERUS	\$0.00	\$0.00	\$0.00	\$0.00
ACLARIS	\$0.00	\$0.00	\$0.00	\$0.00
ACORDA THERAPEUTICS INC	\$989.82	\$989.82	\$0.00	\$0.00
AERIE	\$30,268.33	\$28,474.70	\$0.00	\$0.00
AKARX Inc	\$0.00	\$0.00	\$0.00	\$0.00
AKEBIA THERAPEUTICS INC	\$0.00	\$0.00	\$0.00	\$0.00
AKORN, INC	\$87,443.75	\$61,469.60	\$0.00	\$0.00
ALEXION PHARMACEUTICALS INC	\$915,095.70	\$898,620.10	\$0.00	\$0.00
ALFASIGMA USA	\$4,288.70	\$4,168.39	\$0.00	\$0.00
ALK ABELLO INC	\$0.00	\$0.00	\$0.00	\$0.00
ALKERMES INC	\$769,177.32	\$759,586.59	\$41,516.03	\$39,954.57
ALLEGIS	\$12,095.79	\$7,678.19	\$0.00	\$0.00
ALLERGAN PHARM	\$5,055,167.36	\$4,841,869.26	\$0.00	\$0.00
ALMATICA	\$25,380.66	\$23,901.36	\$0.00	\$0.00
AMAG PHARMACEUTICALS, INC	\$100,195.21	\$100,195.21	\$34,326.79	\$27,028.94
AMARIN	\$127,591.20	\$122,492.96	\$0.00	\$0.00
AMGEN	\$3,668,809.23	\$3,642,478.81	\$495,706.41	\$472,668.44
AMNEAL PHARMACEUTICALS LLC	\$1,641,714.68	\$1,613,870.60	\$0.00	\$0.00
ANTARES PHARMA INC	\$51,536.15	\$49,390.36	\$0.00	\$0.00
AQUA PHARMACEUTICALS	\$0.00	\$0.00	\$0.00	\$0.00
ARBOR	\$333,053.19	\$322,513.67	\$0.00	\$0.00
ARKRAY USA INC	\$675.44	\$547.32	\$0.00	\$0.00
ASCEND THERAPEUTICS US, LLC	\$508,246.85	\$332,409.35	\$0.00	\$0.00

Supplemental Rebate Agreements in Place during SFY 2021				
Manufacturer Name	Amount Plan Paid for Products During Contract Term	Amount Plan Paid to Pharmacies/ Providers for Products Under Contract During Contract Term	Total Supplemental Rebates Invoiced	Total Supplemental Rebates Collected
ASEGUA	\$1,545,758.90	\$1,545,758.90	\$312,010.28	\$312,010.29
ASSERTIO	\$110,496.36	\$106,467.26	\$0.00	\$0.00
ASTELLAS PHARMA US	\$197,561.73	\$188,659.84	\$0.00	\$0.00
ASTRA ZENECA	\$1,943,597.90	\$1,906,307.86	\$0.00	\$0.00
AVANIR PHARMACEUTICALS	\$33,980.03	\$32,523.33	\$0.00	\$0.00
AVEXIS	\$0.00	\$0.00	\$0.00	\$0.00
AVION PHARMACEUTICALS	\$12,611.67	\$11,804.55	\$0.00	\$0.00
BANNER LIFE SCIENCES	\$0.00	\$0.00	\$0.00	\$0.00
BAYER	\$393,466.82	\$392,947.36	\$0.00	\$0.00
BAYER DIAGNOSTICS	\$0.00	\$0.00	\$0.00	\$0.00
BECTON DICKINSON	\$466,993.26	\$433,935.26	\$43,253.26	\$51,760.19
BIODELIVERY SCIENCES INT	\$183,144.00	\$173,115.10	\$0.00	\$0.00
BIOGEN	\$755,171.56	\$754,873.86	\$2,114.91	\$1,686.91
BIOHAVEN PHARMACEUTICALS	\$472,409.13	\$447,506.64	\$28,709.44	\$28,669.63
BIOVENTUS LLC	\$0.00	\$0.00	\$0.00	\$0.00
BOEHRINGER INGELHEIM	\$5,047,609.82	\$4,753,735.85	\$34,877.42	\$44,873.01
BRISTOL-MYERS SQUIBB	\$4,185,661.98	\$4,086,905.61	\$72,101.59	\$70,973.67
CELGENE CORP	\$0.00	\$0.00	\$0.00	\$0.00
CELLTRION	\$1,637.94	\$258.56	\$0.00	\$0.00
CEQR CORPORATION	\$0.00	\$0.00	\$0.00	\$0.00
CHIESI USA	\$11,092.42	\$10,285.34	\$0.00	\$0.00
CLOVIS ONCOLOGY INC	\$0.00	\$0.00	\$0.00	\$0.00
COHERUS BIOSCIENCES	\$36,923.70	\$36,923.70	\$495.99	\$0.00
COLLEGIUM PHARMACEUTICALS	\$208,758.54	\$196,938.43	\$0.00	\$0.00
COVIS PHARMA	\$19,219.42	\$18,020.81	\$0.00	\$0.00
CROWN LABORATORIES	\$525.73	\$331.11	\$0.00	\$0.00
CSL BEHRING LLC	\$223,154.29	\$223,154.29	\$0.00	\$0.00
CUMBERLAND PHARMACEUTICALS	\$52.67	\$42.98	\$0.00	\$0.00

Supplemental Rebate Agreements in Place during SFY 2021				
Manufacturer Name	Amount Plan Paid for Products During Contract Term	Amount Plan Paid to Pharmacies/ Providers for Products Under Contract During Contract Term	Total Supplemental Rebates Invoiced	Total Supplemental Rebates Collected
CURRAX PHARMACEUTICALS LLC	\$3,847.90	\$3,983.45	\$0.00	\$0.00
CUTANEA LIFE SCIENCES INC	\$0.00	\$0.00	\$0.00	\$0.00
CYCLE PHARMACEUTICALS	\$0.00	\$0.00	\$0.00	\$0.00
DERMIRA, INC	\$0.00	\$0.00	\$0.00	\$0.00
DEXCOM	\$337,644.91	\$313,218.60	\$207,216.27	\$187,943.98
DIGESTIVE CARE	\$7,996.89	\$7,607.54	\$0.00	\$0.00
DUCHESNAY USA, INC	\$8,931.68	\$8,195.24	\$0.00	\$0.00
EGALET CORPORATION	\$0.00	\$0.00	\$0.00	\$0.00
EISAI INC	\$252,690.74	\$247,997.68	\$0.00	\$0.00
ELECTROCORE	\$0.00	\$0.00	\$0.00	\$0.00
ELI LILLY & COMPANY	\$7,109,759.10	\$6,784,957.73	\$618,531.83	\$609,542.48
EMD SERONO	\$977,383.34	\$967,000.15	\$4,881.82	\$4,881.80
EMERGENT DEVICES	\$168,194.12	\$168,194.12	\$15,085.77	\$15,085.74
ENCORE DERMATOLOGY, INC	\$1,862.39	\$2,323.36	\$0.00	\$0.00
ENDO PHARMACEUTICAL SOLUTIONS	\$118,983.64	\$116,440.14	\$0.00	\$0.00
EPI HEALTH LLC	\$1,232.93	\$1,192.15	\$0.00	\$0.00
ESPERION THERAPEUTICS	\$3,979.40	\$3,523.55	\$0.00	\$0.00
EXELIXIS INC	\$9,914.51	\$9,914.51	\$0.00	\$0.00
EXELTIS USA DERMATOLOGY	\$3,809.46	\$3,519.99	\$0.00	\$0.00
EYEVANCE	\$3,396.62	\$3,276.56	\$0.00	\$0.00
FERRING	\$471,431.64	\$471,185.59	\$174,615.49	\$174,615.51
FIDIA PHARMA USA INC	\$0.00	\$0.00	\$0.00	\$0.00
FORTOVIA THERAPEUTICS	\$0.00	\$0.00	\$0.00	\$0.00
FORWARD SCIENCE	\$0.00	\$0.00	\$0.00	\$0.00
FOUGERA PHARMACEUTICALS INC	\$227,412.73	\$103,394.48	\$0.00	\$0.00
FRESENIUS USA	\$3,036.17	\$2,975.61	\$0.00	\$0.00

Supplemental Rebate Agreements in Place during SFY 2021				
Manufacturer Name	Amount Plan Paid for Products During Contract Term	Amount Plan Paid to Pharmacies/ Providers for Products Under Contract During Contract Term	Total Supplemental Rebates Invoiced	Total Supplemental Rebates Collected
GALDERMA	\$41,898.18	\$39,775.03	\$0.00	\$0.00
GALEN	\$0.00	\$0.00	\$0.00	\$0.00
GENENTECH	\$3,409,235.86	\$3,408,977.57	\$77,120.59	\$64,276.51
GENESIS HEALTH TECHNOLOGIES	\$0.00	\$0.00	\$0.00	\$0.00
GILEAD SCIENCES INC	\$17,288,926.01	\$16,681,131.55	\$0.00	\$0.00
GLAXO SMITHKLINE	\$3,747,568.18	\$3,548,913.01	\$59,377.80	\$58,317.35
GLENMARK THERAPEUTICS INC	\$656,378.04	\$621,907.52	\$0.00	\$0.00
GREENWICH BIOSCIENCES	\$113,667.10	\$113,667.10	\$0.00	\$0.00
GREER LABORATORIES, INC	\$0.00	\$0.00	\$0.00	\$0.00
GRIFOLS USA, LLC	\$232,508.37	\$227,547.95	\$0.00	\$0.00
HELSINN THERAPEUTICS	\$598.21	\$598.21	\$0.00	\$0.00
HIKMA AMERICAS	\$571,261.71	\$283,998.09	\$0.00	\$0.00
HORIZON PHARMA USA, INC	\$1,134,671.07	\$1,124,094.00	\$0.00	\$0.00
HTL-STREFA	\$3,001.23	\$2,780.00	\$0.00	\$0.00
INDIVIOR	\$66,793.63	\$64,297.77	\$0.00	\$0.00
INSMED	\$0.00	\$0.00	\$0.00	\$0.00
INSULET	\$8,088.16	\$7,779.49	\$856.03	\$754.79
INSYS THERAPEUTICS, INC	\$0.00	\$0.00	\$0.00	\$0.00
IPSEN BIOPHARMACEUTICALS INC	\$0.00	\$0.00	\$0.00	\$0.00
IRONSHORE	\$13,110.49	\$12,347.89	\$0.00	\$0.00
IRONWOOD PHARMACEUTICALS INC	\$0.00	\$0.00	\$0.00	\$0.00
JAZZ	\$423,843.13	\$451,823.79	\$0.00	\$0.00
JOHNSON and JOHNSON	\$7,991,749.76	\$7,794,718.05	\$33,514.84	\$36,594.82
JOURNEY MEDICAL	\$61,741.86	\$59,468.29	\$0.00	\$0.00
KALA PHARMACEUTICALS INC	\$2,651.91	\$2,515.75	\$0.00	\$0.00

Supplemental Rebate Agreements in Place during SFY 2021				
Manufacturer Name	Amount Plan Paid for Products During Contract Term	Amount Plan Paid to Pharmacies/ Providers for Products Under Contract During Contract Term	Total Supplemental Rebates Invoiced	Total Supplemental Rebates Collected
KOWA PHARMACEUTICALS	\$51,812.41	\$49,186.89	\$0.00	\$0.00
KYOWA KIRIN	\$23,728.36	\$23,307.75	\$0.00	\$0.00
LEO PHARMA, INC	\$755.10	\$726.20	\$0.00	\$0.00
LIFESCAN	\$46,005.41	\$43,123.55	\$0.00	\$0.00
LUPIN PHARMACEUTICALS, INC	\$1,627,705.88	\$943,065.60	\$0.00	\$0.00
MAGNA PHARMACEUTICALS	\$0.00	\$0.00	\$0.00	\$0.00
MALLINCKRODT	\$250,255.75	\$141,087.70	\$0.00	\$0.00
MANNKIND CORPORATION	\$10,224.32	\$9,593.88	\$0.00	\$0.00
MAYNE PHARMA	\$160,610.15	\$72,534.04	\$0.00	\$0.00
MEDEXUS PHARMA	\$4,830.38	\$4,830.38	\$0.00	\$0.00
MELINTA THERAPEUTICS INC	\$42,641.26	\$41,002.80	\$0.00	\$0.00
MERCK & CO, INC	\$3,154,411.08	\$2,987,489.06	\$0.00	\$0.00
METUCHEN	\$0.00	\$0.00	\$0.00	\$0.00
MILLENNIUM PHARMACEUTICALS	\$0.00	\$0.00	\$0.00	\$0.00
MILLICENT	\$10,032.40	\$9,405.99	\$0.00	\$0.00
MINIMED DISTRIBUTION CORP	\$0.00	\$0.00	\$0.00	\$0.00
MISSION	\$38,040.56	\$36,863.22	\$0.00	\$0.00
MYLAN PHARMACEUTICALS INC	\$1,565,443.96	\$1,155,780.61	\$0.00	\$0.00
NABRIVA	\$0.00	\$0.00	\$0.00	\$0.00
NEOS THERAPEUTICS LP	\$2,886.01	\$2,793.97	\$0.00	\$0.00
NESTLE HEALTH SCIENCE	\$64,335.12	\$58,707.87	\$0.00	\$0.00
NEURELIS	\$22,802.45	\$22,158.01	\$402.49	\$402.50
NEUROCRINE BIOSCIENCES INC	\$508,223.93	\$490,351.78	\$0.00	\$0.00
NODEN PHARMA USA	\$0.00	\$0.00	\$0.00	\$0.00
NOVARTIS	\$3,320,910.05	\$3,275,597.22	\$26,599.31	\$23,735.41

Supplemental Rebate Agreements in Place during SFY 2021				
Manufacturer Name	Amount Plan Paid for Products During Contract Term	Amount Plan Paid to Pharmacies/ Providers for Products Under Contract During Contract Term	Total Supplemental Rebates Invoiced	Total Supplemental Rebates Collected
NOVEN THERAPEUTICS LLC	\$7,804.55	\$6,873.77	\$0.00	\$0.00
NOVO NORDISK	\$5,692,727.32	\$5,364,730.14	\$449,805.15	\$400,226.37
OPKO PHARMACEUTICALS LLC	\$19,786.80	\$18,643.85	\$0.00	\$0.00
OPTINOSE US, INC	\$6,911.45	\$6,512.22	\$0.00	\$0.00
OREXO	\$8,291.87	\$7,938.44	\$0.00	\$0.00
ORTHOGENRX	\$0.00	\$0.00	\$0.00	\$0.00
OTSUKA	\$2,760,291.20	\$2,676,299.59	\$117,235.54	\$105,685.54
PARATEK PHARMACEUTICALS, INC	\$27,012.34	\$27,012.34	\$0.00	\$0.00
PARI RESPIRATORY	\$605.94	\$547.34	\$0.00	\$0.00
PERRIGO	\$106,867.56	\$101,346.22	\$0.00	\$0.00
PFIZER US PHARM	\$2,393,132.84	\$2,338,001.83	\$0.00	\$0.00
PHARMING HEALTHCARE INC	\$0.00	\$0.00	\$0.00	\$0.00
PIERRE FABRE PHARMA INC	\$0.00	\$0.00	\$0.00	\$0.00
PURDUE PHARMA	\$116,874.82	\$109,503.43	\$0.00	\$0.00
RADIUS HEALTH INC	\$0.00	\$0.00	\$0.00	\$0.00
RECKITT BENCKISER	\$53.31	\$53.31	\$7.86	\$7.86
REDHILL BIOPHARMA	\$41,532.00	\$38,572.22	\$0.00	\$0.00
REGENERON PHARMACEUTICALS INC	\$1,327.35	\$1,283.02	\$0.00	\$0.00
RETROPHIN INC	\$0.00	\$0.00	\$0.00	\$0.00
RHODES PHARMACEUTICALS LP	\$153,106.06	\$116,352.56	\$0.00	\$0.00
ROCHE DIAGNOSTICS	\$4,984.80	\$4,597.91	\$0.00	\$0.00
SANDOZ INC	\$562,085.14	\$338,854.93	\$15,995.40	\$15,995.35
SANOFI - AVENTIS	\$354,002.15	\$333,381.21	\$91,468.94	\$28,730.03
SCILEX PHARMACEUTICALS INC	\$697,074.91	\$673,372.07	\$0.00	\$0.00
SEBELA PHARMACEUTICALS INC	\$2,857.69	\$2,753.04	\$0.00	\$0.00

Supplemental Rebate Agreements in Place during SFY 2021				
Manufacturer Name	Amount Plan Paid for Products During Contract Term	Amount Plan Paid to Pharmacies/ Providers for Products Under Contract During Contract Term	Total Supplemental Rebates Invoiced	Total Supplemental Rebates Collected
SECURA BIO	\$0.00	\$0.00	\$0.00	\$0.00
SHIONOGI & COMPANY, INC	\$7,956.00	\$7,956.00	\$0.00	\$0.00
SHIRE-RICHWOOD	\$1,261,725.38	\$1,213,885.80	\$0.00	\$0.00
SK LIFE SCIENCE	\$4,136.38	\$3,718.27	\$0.00	\$0.00
SOBI INC	\$612,219.69	\$611,626.79	\$0.00	\$0.00
SUN PHARMA INDUSTRIES INC	\$624,469.43	\$361,366.00	\$0.00	\$0.00
SUNOVION	\$3,034,434.22	\$2,887,015.16	\$0.00	\$0.00
SUPERNUS PHARMACEUTICALS, INC	\$144,925.75	\$137,202.11	\$0.00	\$0.00
SYNERGY	\$0.00	\$0.00	\$0.00	\$0.00
TAKEDA	\$637,470.92	\$612,836.62	\$0.00	\$0.00
TERSERA THERAPEUTICS	\$25,002.21	\$25,185.95	\$0.00	\$0.00
TESARO, INC	\$0.00	\$0.00	\$0.00	\$0.00
TEVA	\$3,123,117.27	\$2,414,045.63	\$0.00	\$0.00
TherapeuticsMD INC	\$72,874.50	\$69,961.43	\$0.00	\$0.00
TOLMAR PHARMACEUTICALS INC	\$42,527.40	\$41,171.72	\$0.00	\$0.00
TRIS PHARMA	\$35,354.34	\$29,087.16	\$0.00	\$0.00
TRIVIDIA HEALTH	\$829,757.87	\$764,435.99	\$621,244.80	\$372,665.03
UCB INC	\$1,388,989.09	\$1,318,081.34	\$0.00	\$0.00
UNITED THERAPEUTICS CORP	\$0.00	\$0.00	\$0.00	\$0.00
UPSHER-SMITH	\$437,708.26	\$320,537.10	\$0.00	\$0.00
US WORLDMEDS, LLC	\$6,111.43	\$5,927.84	\$0.00	\$0.00
VALEANT PHARMACEUTICALS	\$890,901.86	\$748,869.87	-\$0.01	\$765.56
VELOXIS PHARMACEUTICALS	\$0.00	\$0.00	\$0.00	\$0.00
VERTICAL PHARMACEUTICALS	\$596.24	\$962.19	\$0.00	\$0.00
VIFOR PHARMA, INC	\$24,914.33	\$23,676.75	\$0.00	\$0.00
VIVUS	\$9,150.93	\$9,101.36	\$0.00	\$0.00
VYERA PHARMACEUTICALS	\$0.00	\$0.00	\$0.00	\$0.00

Supplemental Rebate Agreements in Place during SFY 2021				
Manufacturer Name	Amount Plan Paid for Products During Contract Term	Amount Plan Paid to Pharmacies/ Providers for Products Under Contract During Contract Term	Total Supplemental Rebates Invoiced	Total Supplemental Rebates Collected
VYNE PHARMACEUTICALS INC	\$6,901.18	\$6,616.90	\$0.00	\$0.00
WOMENS CHOICE PHARMACEUTICALS	\$1,929.85	\$1,762.47	\$888.18	\$888.20
XERIS	\$1,384.34	\$1,267.37	\$0.00	\$0.00
XSANVITA, LLC	\$0.00	\$0.00	\$0.00	\$0.00
ZEALAND PHARMA US INC	\$0.00	\$0.00	\$0.00	\$0.00
ZIMMER US, INC	\$0.00	\$0.00	\$0.00	\$0.00

HEALTH PLAN OF NEVADA MEDICAID

Supplemental Rebate Agreement Report

State Fiscal Year 2021 (July 1, 2020 to June 30, 2021)

The overall drug rebate process follows the Omnibus Budget Reconciliation Act of 1990 (OBRA '90) as codified in Section 1927 of the Social Security Act (42 U.S.C. 1396r-8) and regulations promulgated by the Centers for Medicare & Medicaid Services (CMS). Under the Medicaid drug rebate program (MDRP), drug manufacturers must provide rebates to the federal government and states as a condition of having their drugs covered by Medicaid. The MDRP helps lower Medicaid prescription drug spending by ensuring that state Medicaid agencies receive discounts in the form of rebates on covered outpatient drugs. In order for their covered outpatient drugs to be covered and reimbursed by state Medicaid agencies, pharmaceutical manufacturers must enter into and have in effect the National Drug Rebate Agreement (NDRA) with the Secretary of the United States Department of Health and Human Services (HHS). The NDRA provides for the payment of Federal rebates by pharmaceutical manufacturers. Nevada Medicaid and the other state Medicaid Programs are third party beneficiaries of the NDRAs. The formulas for calculating the Federal unit rebate amount (URA) are set out by Federal statute.

States may also directly negotiate with manufacturers for voluntary supplemental rebates on top of federally required rebates. States may enter separate or supplemental drug rebate agreements as long as such agreements achieve drug rebates equal to or greater than the drug rebates set forth in the Secretary's national rebate agreement with drug manufacturers, which is published at 56 F.R. 7049 (1991).

The supplemental rebate does not reduce what is being paid under the NDRA but instead, provides an additional tool for states to help manage prescription drug spend. Pharmaceutical manufacturers enter into supplemental rebate agreements (SRA) with Managed Care Organizations (MCOs) to ensure preferred status on the MCOs' Preferred Drug List.

The SRAs below are between the manufacturers and Health Plan of Nevada through its Pharmacy Benefit Manager (PBM). Generally, the SRAs are in effect for one calendar year beginning on January 1st and terminating on December 31st. In some instances, the SRA can have an alternative start date as a result of either newly contracted drugs or new NDCs (National Drug Codes) released for drugs currently under contract. Additionally, there are factors that may cause a contract to have a non-December 31st end date such as a product moving to non-preferred status

Supplemental rebates are calculated based upon two different types of calculations at the unit level:

- "Percentage of WAC" - set percentage of the drug's published wholesale acquisition cost (WAC).
- "GNUP" (Guaranteed Net Unit Price) - WAC minus the Federal URA minus the GNUP.
 - In the event a drug's WAC minus the Federal URA is lower than the GNUP, the supplemental rebate rate is zero.

- Even though there are instances when the GNUP contract does not produce supplemental rebate savings, they remain in place to give price protection in case the manufacturer raises the drug price during the contract term.

The type of calculation used for a particular product is defined within a manufacturer's SRA with Health Plan of Nevada.

Section F of the SRA provides confidentiality assurance that the State and the manufacturer agree to maintain confidentiality and to not disclose pricing information or pricing related terms and conditions.

Health Plan of Nevada had 136 total number of SRAs in place that were in effect during a portion of State Fiscal Year 2021 (July 1, 2020 – June 30, 2021) (hereinafter referred to as SFY 2021). Table 1 below summarizes the agreements:

Table 1 Row Definitions:

- Number of Contracts - The count of signed SRAs that were in force during some period within SFY 2021.
- Number of Unique Manufacturers Under Contract - The count of unique manufacturers with a signed SRA in force during some period within SFY 2021.
- Amount Plan Paid for Products During Contract Term - The amount Health Plan of Nevada paid for all drugs subject to a manufacturer's SRA during SFY 2021.
 - Example: Drug "A" was subject to an SRA from 01/01/2020 to 12/31/2020 but not under an agreement in 2021. This column would include the amount Health Plan of Nevada paid for Drug "A" for claims paid from 07/01/2020 to 12/31/2020.
- Amount Plan Paid to Pharmacies/Providers for Products Under Contract - The amount Health Plan of Nevada paid to pharmacies and providers for drugs subject to a manufacturer's SRA during SFY 2021.
- Total Supplemental Rebates Invoiced - The supplemental rebate amount invoiced during SFY 2021 to manufacturers for drugs subject to SRAs.
- Total Supplemental Rebates Collected - The supplemental rebate amount collected during SFY 2021 to manufacturers for drugs subject to SRAs.
- Supplemental Rebate Percentage of Drug Spend for Contracted Products - The result of dividing the contract value by the drug spend for contracted drugs, expressed as a percentage.

Table 1

Summary of Supplemental Rebate Agreements in Place during SFY 2021	
Number of Contracts	136
Number of Unique Manufacturers Under Contract	46
Amount Plan Paid for Products During Contract Term	\$ 68,920,428.11
Amount Plan Paid to Pharmacies/Providers for Products Under Contract During Contract Term	\$ 68,920,428.11
Total Supplemental Rebates Invoiced	\$ 9,900,008.26
Total Supplemental Rebates Collected	\$ 9,699,600.20
Supplemental Rebate Percentage of the Total the Plan Paid for Contracted Products	14.36%

Table 2 below lists the SRAs in place during SFY 2021. The list is sorted alphabetically by manufacturer name and by SRA start dates.

Table 2 Column Definitions:

- Manufacturer Name - The name of the entity Health Plan of Nevada has contracted with in the SRA.
- Contract Term - The effective and termination dates of the SRA.

Table 2

Supplemental Rebate Agreements in Place during SFY 2021	
Manufacturer Name	Contract Term
ABBOTT DC	07/01/2020 - 06/30/2021
ABBVIE	07/01/2020 - 06/30/2021
ADAPT	07/01/2020 - 06/30/2021
AERIE	07/01/2020 - 06/30/2021
ALKERMES	07/01/2020 - 06/30/2021
AMGEN	07/01/2020 - 06/30/2021
ASEGUA	07/01/2020 - 06/30/2021
ASTRA ZENECA	07/01/2020 - 06/30/2021
BAUSCH HEALTH	07/01/2020 - 06/30/2021
BECTON DICKINSON	07/01/2020 - 06/30/2021
BIOGEN	07/01/2020 - 06/30/2021
BIOHAVEN	09/01/2020 - 06/30/2021
BMS	07/01/2020 - 06/30/2021
BOEHRINGER INGLH	07/01/2020 - 06/30/2021
CHIESI	07/01/2020 - 06/30/2021
DEXCOM	07/01/2020 - 06/30/2021

Supplemental Rebate Agreements in Place during SFY 2021	
Manufacturer Name	Contract Term
DEY	07/01/2020 - 06/30/2021
ELI LILLY	07/01/2020 - 06/30/2021
FERRING	07/01/2020 - 06/30/2021
FRESENIUS KABI	07/01/2020 - 06/30/2021
GSK	07/01/2020 - 06/30/2021
HIKMA	07/01/2020 - 06/30/2021
J&J	07/01/2020 - 06/30/2021
LIFESCAN	07/01/2020 - 06/30/2021
MERCK & CO INC	07/01/2020 - 06/30/2021
NEUROCRINE	07/01/2020 - 06/30/2021
NOVARTIS	07/01/2020 - 06/30/2021
OTSUKA	07/01/2020 - 06/30/2021
PARATEK	07/01/2020 - 06/30/2021
PFIZER	07/01/2020 - 06/30/2021
RADIUS HEALTH	07/01/2020 - 06/30/2021
REDHILL	10/01/2020 - 06/30/2021
REGENERON	01/01/2021 - 06/30/2021
RELYPSA	07/01/2020 - 06/30/2021
SANDOZ	07/01/2020 - 06/30/2021
SANOFI-AVE	07/01/2020 - 06/30/2021
SHIONOGI PHARMA	07/01/2020 - 06/30/2021
SHIRE	07/01/2020 - 06/30/2021
SMITH&NEPHEW	07/01/2020 - 06/30/2021
SUN	07/01/2020 - 06/30/2021
TAKEDA	07/01/2020 - 06/30/2021
TERSERA	07/01/2020 - 06/30/2021
THER-RX	07/01/2020 - 06/30/2021
UCB	07/01/2020 - 06/30/2021
VIIV	07/01/2020 - 06/30/2021
XERIS	07/01/2020 - 06/30/2021

Table 3 below provides the values for supplemental rebates. Table 3 is sorted by Manufacturer Name.

Table 3 Column Definitions:

- Manufacturer Name - The name of the entity the State has contracted with in the SRA.
- Amount Plan Paid for Products During Contract Term - The amount Health Plan of Nevada paid for all drugs subject to a manufacturer’s SRA during SFY 2021.

- Example: Drug “A” was subject to an SRA from 01/01/2020 to 12/31/2020 but not under an agreement in 2021. This column would include the amount Health Plan of Nevada paid for Drug “A” for claims paid from 07/01/2020 to 12/31/2020.
- Amount Plan Paid to Pharmacies/Providers for Products Under Contract - The amount Health Plan of Nevada paid to pharmacies and providers for drugs subject to a manufacturer’s SRA during SFY 2021.
- Total Supplemental Rebates Invoiced - The supplemental rebate amount invoiced during SFY 2021 to manufacturers for drugs subject to SRAs.
- Total Supplemental Rebates Collected - The supplemental rebate amount collected during SFY 2021 to manufacturers for drugs subject to SRAs.

Table 3

Supplemental Rebate Agreements in Place during Fiscal Year 2021				
Manufacturer Name	Amount Plan Paid for Products During Contract Term	Amount Plan Paid to Pharmacies/ Providers for Products Under Contract During Contract Term	Total Supplemental Rebates Invoiced	Total Supplemental Rebates Collected
NVMCO HPN SRA 1	\$28,231.87	\$28,231.87	\$5,073.36	\$2,993.16
NVMCO HPN SRA 2	\$1,455,342.14	\$1,455,342.14	\$29,288.74	\$29,248.69
NVMCO HPN SRA 3	\$2,588,576.63	\$2,588,576.63	\$59,026.69	\$49,914.91
NVMCO HPN SRA 4	\$94,132.90	\$94,132.90	\$0.00	\$0.00
NVMCO HPN SRA 5	\$15,895.06	\$15,895.06	\$1,561.64	\$1,578.25
NVMCO HPN SRA 6	\$25,704.00	\$25,704.00	\$1,785.00	\$1,759.40
NVMCO HPN SRA 7	\$22,325.98	\$22,325.98	\$3,656.00	\$3,671.11
NVMCO HPN SRA 8	\$311,835.53	\$311,835.53	\$7,659.59	\$7,663.96
NVMCO HPN SRA 9	\$5,461,029.71	\$5,461,029.71	\$535,084.44	\$527,714.09
NVMCO HPN SRA 10	\$1,645.56	\$1,645.56	\$0.00	\$0.00
NVMCO HPN SRA 11	\$2,496,621.47	\$2,496,621.47	\$202,930.71	\$188,347.17
NVMCO HPN SRA 12	\$12,767.38	\$12,767.38	\$5,319.74	\$5,319.74
NVMCO HPN SRA 13	\$98,875.53	\$98,875.53	\$7,013.17	\$7,009.55
NVMCO HPN SRA 14	\$358,243.35	\$358,243.35	\$29,143.96	\$28,488.99
NVMCO HPN SRA 15	\$100,755.45	\$100,755.45	\$34,550.46	\$34,296.66
NVMCO HPN SRA 16	\$11,310.35	\$11,310.35	\$674.00	\$791.10
NVMCO HPN SRA 17	\$171,782.19	\$171,782.19	\$15,459.97	\$15,778.73
NVMCO HPN SRA 18	\$278,177.06	\$278,177.06	\$45,908.91	\$35,338.91
NVMCO HPN SRA 19	\$9,231.70	\$9,231.70	\$461.67	\$320.66
NVMCO HPN SRA 20	\$28,790.10	\$28,790.10	\$3,402.00	\$3,473.38
NVMCO HPN SRA 21	\$44,478.68	\$44,478.68	\$10,841.74	\$10,783.64
NVMCO HPN SRA 22	\$27,790.57	\$27,790.57	\$281.85	\$133.89
NVMCO HPN SRA 23	\$485,522.56	\$485,522.56	\$160,138.24	\$159,183.61
NVMCO HPN SRA 24	\$31,098.30	\$31,098.30	\$3,570.98	\$3,631.80

Supplemental Rebate Agreements in Place during Fiscal Year 2021

Manufacturer Name	Amount Plan Paid for Products During Contract Term	Amount Plan Paid to Pharmacies/ Providers for Products Under Contract During Contract Term	Total Supplemental Rebates Invoiced	Total Supplemental Rebates Collected
NVMCO HPN SRA 25	\$3,622,045.50	\$3,622,045.50	\$301,968.09	\$272,445.31
NVMCO HPN SRA 26	\$822,769.50	\$822,769.50	\$90,177.75	\$90,184.78
NVMCO HPN SRA 27	\$9,976.96	\$9,976.96	\$4,681.25	\$4,547.17
NVMCO HPN SRA 28	\$180,284.96	\$180,284.96	\$12,913.45	\$11,947.29
NVMCO HPN SRA 29	\$466,038.51	\$466,038.51	\$14,898.68	\$14,804.49
NVMCO HPN SRA 30	\$16,189,416.40	\$16,189,416.40	\$975,331.18	\$963,627.05
NVMCO HPN SRA 31	\$973,323.52	\$973,323.52	\$58,095.61	\$57,995.06
NVMCO HPN SRA 32	\$66,002.68	\$66,002.68	\$15,291.84	\$15,192.77
NVMCO HPN SRA 33	\$174,250.36	\$174,250.36	\$36,847.86	\$36,932.47
NVMCO HPN SRA 34	\$955,028.02	\$955,028.02	\$118,654.61	\$114,665.50
NVMCO HPN SRA 35	\$2,208,261.68	\$2,208,261.68	\$564,114.65	\$559,804.26
NVMCO HPN SRA 36	\$1,290,576.00	\$1,290,576.00	\$122,360.00	\$131,058.64
NVMCO HPN SRA 37	\$1,094,498.32	\$1,094,498.32	\$49,460.81	\$48,855.32
NVMCO HPN SRA 38	\$259,220.50	\$259,220.50	\$53,387.20	\$52,710.97
NVMCO HPN SRA 39	\$3,153,926.82	\$3,153,926.82	\$2,723,912.49	\$2,721,786.79
NVMCO HPN SRA 40	\$54,355.73	\$54,355.73	\$4,324.66	\$4,729.40
NVMCO HPN SRA 41	\$14,207,016.92	\$14,207,016.92	\$2,648,520.00	\$2,588,222.41
NVMCO HPN SRA 42	\$108,501.24	\$108,501.24	\$45,115.41	\$45,010.66
NVMCO HPN SRA 43	\$6,006,411.38	\$6,006,411.38	\$167,407.09	\$138,254.06
NVMCO HPN SRA 44	\$532,540.16	\$532,540.16	\$221,503.64	\$204,670.44
NVMCO HPN SRA 45	\$1,080,674.60	\$1,080,674.60	\$408,247.36	\$406,269.37
NVMCO HPN SRA 46	\$1,305,144.28	\$1,305,144.28	\$99,961.77	\$98,444.59

SilverSummit Healthplan
Supplemental Rebate Agreement Report
State Fiscal Year 2021 (July 1, 2020 to June 30, 2021)

The overall drug rebate process follows the Omnibus Budget Reconciliation Act of 1990 (OBRA '90) as codified in Section 1927 of the Social Security Act (42 U.S.C. 1396r-8) and regulations promulgated by the Centers for Medicare & Medicaid Services (CMS). Under the Medicaid drug rebate program (MDRP), drug manufacturers must provide rebates to the federal government and states as a condition of having their drugs covered by Medicaid. The MDRP helps lower Medicaid prescription drug spending by ensuring that state Medicaid agencies receive discounts in the form of rebates on covered outpatient drugs. In order for their covered outpatient drugs to be covered and reimbursed by state Medicaid agencies, pharmaceutical manufacturers must enter into and have in effect the National Drug Rebate Agreement (NDRA) with the Secretary of the United States Department of Health and Human Services (HHS). The NDRA provides for the payment of Federal rebates by pharmaceutical manufacturers. Nevada Medicaid and the other state Medicaid Programs are third party beneficiaries of the NDRA. The formulas for calculating the Federal unit rebate amount (URA) are set out by Federal statute.

States may also directly negotiate with manufacturers for voluntary supplemental rebates on top of federally required rebates. States may enter separate or supplemental drug rebate agreements as long as such agreements achieve drug rebates equal to or greater than the drug rebates set forth in the Secretary's national rebate agreement with drug manufacturers, which is published at 56 F.R. 7049 (1991).

The supplemental rebate does not reduce what is being paid under the NDRA but instead, provides an additional tool for states to help manage prescription drug spend. Pharmaceutical manufacturers enter into supplemental rebate agreements (SRA) with state Medicaid agencies to ensure preferred status on the states' Preferred Drug Lists.

The Nevada Medicaid Supplemental Drug Rebate Program (NMSDRP) has been in effect since January 1, 2012. The SRAs are between the manufacturers and the Nevada Department of Health and Human Services, Division of Health Care Financing and Policy (DHCFP). Generally, the SRAs are in effect for one calendar year beginning on January 1st and terminating on December 31st. In some instances, the SRA can have an alternative start date as a result of either newly contracted drugs or new NDCs (National Drug Codes) released for drugs currently under contract. Additionally, there are factors that may cause a contract to have a non-December 31st end date such as a product moving to non-preferred status or to coincide with planned Silver State Scripts Board (SSSB) review.

During State Fiscal Year 2021, the rebates negotiated under the NMSDRP only applied to Medicaid fee-for-service (FFS) utilization. The other entities, authorized under SB378 to participate in the Medicaid FFS PDL, did not elect to participate.

Supplemental rebates are calculated based upon two different types of calculations at the unit level:

- “Percentage of WAC” - set percentage of the drug’s published wholesale acquisition cost (WAC).
- “GNUP” (Guaranteed Net Unit Price) - WAC minus the Federal URA minus the GNUP.
 - In the event a drug’s WAC minus the Federal URA is lower than the GNUP, the supplemental rebate rate is zero.
 - Even though there are instances when the GNUP contract does not produce supplemental rebate savings, they remain in place to give Nevada Medicaid price protection in case the manufacturer raises the drug price during the contract term.

The type of calculation used for a particular product is defined within a manufacturer’s SRA with SilverSummit Healthplan

Section F of the SRA provides confidentiality assurance that the State and the manufacturer agree to maintain confidentiality and to not disclose pricing information or pricing related terms and conditions.

SilverSummit Healthplan had 196 SRAs in place that were in effect during a portion of State Fiscal Year 2021(July 1, 2020 – June 30, 2021) (hereinafter referred to as SFY 2021). Table 1 below summarizes the agreements:

Table 1 Row Definitions:

- Number of Contracts - The count of signed SRAs that were in force during some period within SFY 2021.
- Number of Unique Manufacturers Under Contract - The count of unique manufacturers with a signed SRA in force during some period within SFY 2021.
- Amount Plan Paid for Products During Contract Term - The amount SilverSummit Healthplan paid for all drugs subject to a manufacturer’s SRA during SFY 2021.
 - Example: Drug “A” was subject to an SRA from 01/01/2020 to 12/31/2020 but not under an agreement in 2021. This column would include the amount SilverSummit Healthplan paid for Drug “A” for claims paid from 07/01/2020 to 12/31/2020.

- Amount Plan Paid to Pharmacies/Providers for Products Under Contract - The amount SilverSummit Healthplan paid to pharmacies and providers for drugs subject to a manufacturer’s SRA during SFY 2021.
- Total Supplemental Rebates Invoiced - The supplemental rebate amount invoiced during SFY 2021 to manufacturers for drugs subject to SRAs.
- Total Supplemental Rebates Collected - The supplemental rebate amount collected during SFY 2021 to manufacturers for drugs subject to SRAs.
- Supplemental Rebate Percentage of Drug Spend for Contracted Products - The result of dividing the contract value by the drug spend for contracted drugs, expressed as a percentage.

Table 1

Summary of Supplemental Rebate Agreements in Place during SFY 2021	
Number of Contracts	196
Number of Unique Manufacturers Under Contract	188
Amount Plan Paid for Products During Contract Term	\$32,528,558.42
Amount Plan Paid to Pharmacies/Providers for Products Under Contract During Contract Term	\$32,528,959.92
Total Supplemental Rebates Invoiced	\$1,036,758.98
Total Supplemental Rebates Collected	\$952,656.32
Supplemental Rebate Percentage of the Total the Plan Paid for Contracted Products	3.19%

Table 2 below lists the SRAs in place during SFY 2021. The list is sorted alphabetically by manufacturer name and by SRA start dates.

Table 2 Column Definitions:

- Manufacturer Name - The name of the entity the State has contracted with in the SRA.
- Contract Term - The effective and termination dates of the SRA.

Table 2

Supplemental Rebate Agreements in Place during SFY 2021	
Manufacturer Name	Contract Term
60 DEGREES	1/1/2020-12/31/9999
ABBOTT DIABETES CARE	1/1/2020-12/31/2022
ABBVIE INC	1/1/2017 12/31/9999
ACERUS	4/1/2021-12/31/9999
ACLARIS	10/1/2019-9/30/2020
ACORDA THERAPEUTICS INC	1/1/202012/31/2023
AERIE	1/1/2020-12/31/9999
AKARX Inc	9/1/2020-12/31/9999
AKEBIA THERAPEUTICS INC	1/1/2020-12/31/9999
AKORN, INC	1/1/2020-12/31/2022
ALEXION PHARMACEUTICALS INC	1/1/2020-12/31/9999
ALFASIGMA USA	1/1/2020-12/31/9999
ALK ABELLO INC	1/1/2020-12/31/9999
ALKERMES INC	4/1/2020-12/31/2025
ALLEGIS	4/1/2017-12/31/9999
ALLERGAN PHARM	1/1/2020-12/31/9999
ALMATICA	10/1/2020-12/31/9999
AMAG PHARMACEUTICALS, INC	1/1/2020-12/31/9999
AMARIN	1/1/2020-12/31/9999
AMGEN	1/1/2020-12/31/2022
AMNEAL PHARMACEUTICALS LLC	1/1/2020-12/31/9999
ANTARES PHARMA INC	1/1/2020-12/31/9999
AQUA PHARMACEUTICALS	1/1/2020-3/31/2022
ARBOR	1/1/2020-12/31/2021
ARKRAY USA INC	1/1/2020-12/31/2022
ASCEND THERAPEUTICS US, LLC	1/1/2020-3/31/2022
ASEGUA	1/1/2020-12/31/9999
ASSERTIO	1/1/2020-12/31/9999
ASTELLAS PHARMA US	1/1/2020-12/31/9999
ASTRA ZENECA	1/1/2020-12/31/9999
AVANIR PHARMACEUTICALS	1/1/2020-12/31/2023
AVEXIS	7/1/2019-12/31/2022
AVION PHARMACEUTICALS	1/1/2020-12/31/9999
BANNER LIFE SCIENCES	10/1/2020-12/31/2023
BAYER	1/1/2020-12/31/2022
BAYER DIAGNOSTICS	1/1/2020-12/31/9999
BECTON DICKINSON	1/1/2020-12/31/9999
BIODELIVERY SCIENCES INT	7/1/2019-12/31/9999
BIOGEN	1/1/2020-12/31/9999

Supplemental Rebate Agreements in Place during SFY 2021	
Manufacturer Name	Contract Term
BIOHAVEN PHARMACEUTICALS	4/1/2020-12/31/2022
BIOVENTUS LLC	1/1/2020-12/31/9999
BOEHRINGER INGELHEIM	1/1/2020-12/31/9999
BRISTOL-MYERS SQUIBB	1/1/2020-12/31/9999
CELGENE CORP	1/1/2020-12/31/9999
CELLTRION	10/1/2019-12/31/2020
CEQR CORPORATION	1/1/2021-12/31/9999
CHIESI USA	1/1/2020-12/31/9999
CLOVIS ONCOLOGY INC	1/1/2020-12/31/2022
COHERUS BIOSCIENCES	1/1/2020-12/31/9999
COLLEGIUM PHARMACEUTICALS	7/1/2019-12/31/9999
COVIS PHARMA	1/1/2020-12/31/9999
CROWN LABORATORIES	1/1/2020-12/31/2022
CSL BEHRING LLC	1/1/2020-12/31/9999
CUMBERLAND PHARMACEUTICALS	1/1/2020-12/31/9999
CURRAX PHARMACEUTICALS LLC	1/1/2020-12/31/9999
CUTANEA LIFE SCIENCES INC	1/1/2020-12/31/9999
CYCLE PHARMACEUTICALS	1/1/2020-12/31/9999
DERMIRA, INC	1/1/2020-12/31/9999
DEXCOM	1/1/2020-12/31/9999
DIGESTIVE CARE	1/1/2020-12/31/9999
DUCHESNAY USA, INC	1/1/2020-8/31/2022
EGALET CORPORATION	1/1/2020-12/31/9999
EISAI INC	1/1/2020-12/31/9999
ELECTROCORE	1/1/2020-12/31/9999
ELI LILLY & COMPANY	1/1/2020-12/31/2022
EMD SERONO	1/1/2019-12/31/2021
EMERGENT DEVICES	1/1/2020-12/31/2020
EMERGENT DEVICES	1/1/2020-12/31/9999
ENCORE DERMATOLOGY, INC	1/1/2020-9/30/2021
ENDO PHARMACEUTICAL SOLUTIONS	10/1/2019-12/31/2021
EPI HEALTH LLC	1/1/2020-12/31/9999
ESPERION THERAPEUTICS	4/1/2020-12/31/2022
EXELIXIS INC	1/1/2020-12/31/2021
EXELTIS USA DERMATOLOGY	1/1/2020-12/31/9999
EYEVANCE	1/1/2020-12/31/2022
FERRING	1/1/2020-12/31/9999
FIDIA PHARMA USA INC	1/1/2020-12/31/9999
FORTOVIA THERAPEUTICS	1/1/2020-12/31/2022
FORWARD SCIENCE	1/1/2020-12/31/9999
FOUGERA PHARMACEUTICALS INC	1/1/2020-12/31/2021

Supplemental Rebate Agreements in Place during SFY 2021	
Manufacturer Name	Contract Term
FRESENIUS USA	1/1/2020-12/31/2021
GALDERMA	7/1/2007-12/31/2020
GALDERMA	1/1/2021-12/31/2023
GALEN	1/1/2020-2/28/2022
GENENTECH	1/1/2020-12/31/2022
GENESIS HEALTH TECHNOLOGIES	1/1/2020-12/31/9999
GILEAD SCIENCES INC	1/1/2020-12/31/9999
GLAXO SMITHKLINE	1/1/2019-12/31/2022
GLAXO SMITHKLINE	1/1/2020-12/31/9999
GLENMARK THERAPEUTICS INC	1/1/2020-12/31/9999
GREENWICH BIOSCIENCES	1/1/2020-12/31/2021
GREER LABORATORIES, INC	1/1/2020-12/31/9999
GRIFOLS USA, LLC	1/1/2020-12/31/2022
HELSINN THERAPEUTICS	1/1/2020-8/31/2021
HIKMA AMERICAS	1/1/2020-12/31/9999
HORIZON PHARMA USA, INC	1/1/2020-12/31/9999
HTL-STREFA	4/1/2021-12/31/9999
INDIVIOR	7/1/2019-12/31/9999
INSMED	7/1/2019-12/31/9999
INSULET	1/1/2020-12/31/9999
INSYS THERAPEUTICS, INC	1/1/2015-3/31/2021
IPSEN BIOPHARMACEUTICALS INC	1/1/2020-3/31/2022
IRONSHORE	1/1/2020-12/31/9999
IRONWOOD PHARMACEUTICALS INC	10/1/2017-7/31/2020
JAZZ	4/1/2020-12/31/2022
JOHNSON and JOHNSON	1/1/2017-12/31/2020
JOHNSON and JOHNSON	1/1/2021-8/31/2021
JOURNEY MEDICAL	9/1/2020-12/31/9999
KALA PHARMACEUTICALS INC	1/1/2020-12/31/9999
KOWA PHARMACEUTICALS	1/1/2020-12/31/9999
KYOWA KIRIN	1/1/2020-6/30/2022
LEO PHARMA, INC	1/1/2020-12/31/2022
LIFESCAN	1/1/2020-12/31/9999
LUPIN PHARMACEUTICALS, INC	7/1/2013-6/30/2021
MAGNA PHARMACEUTICALS	4/1/2017-9/30/2020
MALLINCKRODT	10/1/2019-12/31/9999
MANKIND CORPORATION	1/1/2020-12/31/9999
MAYNE PHARMA	1/1/2020-12/31/9999
MEDEXUS PHARMA	1/1/2020-12/31/2021
MELINTA THERAPEUTICS INC	1/1/2020-12/31/9999
MERCK & CO, INC	1/1/2020-12/31/9999

Supplemental Rebate Agreements in Place during SFY 2021	
Manufacturer Name	Contract Term
METUCHEN	1/1/2020-12/31/9999
MILLENNIUM PHARMACEUTICALS	1/1/2021-12/31/2023
MILLICENT	1/1/2020-6/30/2022
MINIMED DISTRIBUTION CORP	1/1/2020-12/31/9999
MISSION	1/1/2020-12/31/9999
MYLAN PHARMACEUTICALS INC	1/1/2020-12/31/2022
NABRIVA	1/1/2020-12/31/9999
NEOS THERAPEUTICS LP	1/1/2020-12/31/9999
NESTLE HEALTH SCIENCE	1/1/2020-12/31/2020
NESTLE HEALTH SCIENCE	1/1/2021-12/31/9999
NEURELIS	10/1/2020-12/31/9999
NEUROCRINE BIOSCIENCES INC	1/1/2020-12/31/9999
NODEN PHARMA USA	1/1/2020-12/31/9999
NOVARTIS	1/1/2020-12/31/9999
NOVEN THERAPEUTICS LLC	1/1/2020-12/31/9999
NOVO NORDISK	1/1/2020-12/31/2021
OPKO PHARMACEUTICALS LLC	1/1/2020-12/31/9999
OPTINOSE US, INC	1/1/2020-12/31/9999
OREXO	7/1/2019-12/31/2021
ORTHOGENRX	1/1/2020-11/12/2022
OTSUKA	1/1/2020-12/31/9999
PARATEK PHARMACEUTICALS, INC	1/1/2020-12/31/2022
PARI RESPIRATORY	1/1/2020-12/31/9999
PERRIGO	1/1/2020-12/31/9999
PFIZER US PHARM	1/1/2020-12/31/9999
PHARMING HEALTHCARE INC	1/1/2020-12/31/9999
PIERRE FABRE PHARMA INC	1/1/2020-12/31/9999
PURDUE PHARMA	10/1/2019-12/31/9999
RADIUS HEALTH INC	1/1/2020-12/31/9999
RECKITT BENCKISER	1/1/2020-12/31/9999
REDHILL BIOPHARMA	1/1/2020-12/31/2023
REGENERON PHARMACEUTICALS INC	10/1/2020-12/31/9999
RETROPHIN INC	1/1/2020-12/31/9999
RHODES PHARMACEUTICALS LP	1/1/2020-8/31/2021
ROCHE DIAGNOSTICS	1/1/2020-12/31/2022
SANDOZ INC	4/1/2020-12/31/9999
SANOFI - AVENTIS	7/1/2013-12/31/9999
SCILEX PHARMACEUTICALS INC	7/1/2019-12/31/9999
SEBELA PHARMACEUTICALS INC	1/1/2020-12/31/2020
SEBELA PHARMACEUTICALS INC	1/1/2021-12/31/9999
SECURA BIO	1/1/2020-12/31/9999

Supplemental Rebate Agreements in Place during SFY 2021	
Manufacturer Name	Contract Term
SHIONOGI & COMPANY, INC	1/1/2020-12/31/2023
SHIRE-RICHWOOD	8/1/2019-8/31/2021
SK LIFE SCIENCE	4/1/2020-12/31/9999
SOBI INC	1/1/2020-12/31/2021
SUN PHARMA INDUSTRIES INC	1/1/2020-12/31/2022
SUNOVION	1/1/202012/31/2022
SUPERNUS PHARMACEUTICALS, INC	1/1/2020-12/31/9999
SYNERGY	4/1/2020-12/31/9999
TAKEDA	10/1/2019-12/31/9999
TERSERA THERAPEUTICS	1/1/2020-12/31/9999
TESARO, INC	4/1/2016-9/30/2020
TEVA	1/1/2020-12/31/9999
TherapeuticsMD INC	1/1/2020-12/31/9999
TOLMAR PHARMACEUTICALS INC	7/1/2017-9/30/2020
TOLMAR PHARMACEUTICALS INC	10/1/2020-12/31/9999
TRIS PHARMA	1/1/2020-12/31/9999
TRIVIDIA HEALTH	1/1/2020-12/31/2022
UCB INC	1/1/2020-12/31/9999
UNITED THERAPEUTICS CORP	1/1/2015-6/30/2021
UPSHER-SMITH	1/1/2020-12/31/9999
US WORLDMEDS, LLC	1/1/2020-8/31/2021
VALEANT PHARMACEUTICALS	1/1/2020-12/31/9999
VELOXIS PHARMACEUTICALS	1/1/2020-12/31/9999
VERTICAL PHARMACEUTICALS	1/1/2020-12/31/9999
VIFOR PHARMA, INC	1/1/2020-12/31/2022
VIVUS	1/1/2020-12/31/9999
VYERA PHARMACEUTICALS	1/1/2020-12/31/9999
VYNE PHARMACEUTICALS INC	1/1/2021-12/31/2023
WOMENS CHOICE PHARMACEUTICALS	1/1/2020-12/31/9999
XERIS	3/1/2020-12/31/9999
XSANVITA, LLC	1/1/2014-12/31/9999
ZEALAND PHARMA US INC	1/1/2020-12/31/9999
ZIMMER US, INC	1/1/2020-12/31/2022

Table 3 below provides the value for supplemental rebates. Table 3 is sorted by Manufacturer Name.

Table 3 Column Definitions:

- Manufacturer Name - The name of the entity the State has contracted with in the SRA.
- Amount Plan Paid for Products During Contract Term - The amount SilverSummit Healthplan paid for all drugs subject to a manufacturer’s SRA during SFY 2021.
 - Example: Drug “A” was subject to an SRA from 01/01/2020 to 12/31/2020 but not under an agreement in 2021. This column would include the amount SilverSummit Healthplan paid for Drug “A” for claims paid from 07/01/2020 to 12/31/2020.
- Amount Plan Paid to Pharmacies/Providers for Products Under Contract - The amount SilverSummit Healthplan paid to pharmacies and providers for drugs subject to a manufacturer’s SRA during SFY 2021.
- Total Supplemental Rebates Invoiced - The supplemental rebate amount invoiced during SFY 2021 to manufacturers for drugs subject to SRAs.
- Total Supplemental Rebates Collected - The supplemental rebate amount collected during SFY 2021 to manufacturers for drugs subject to SRAs.

Table 3

Supplemental Rebate Agreements in Place during SFY 2021				
Manufacturer Name	Amount Plan Paid for Products During Contract Term	Amount Plan Paid to Pharmacies/ Providers for Products Under Contract During Contract Term	Total Supplemental Rebates Invoiced	Total Supplemental Rebates Collected
60 DEGREES	\$-	\$-	\$-	\$-
ABBOTT DIABETES CARE	\$9,869.97	\$9,869.97	\$542.30	\$536.80
ABBVIE INC	\$2,490,340.69	\$2,490,340.69	\$132,236.12	\$127,943.22
ACERUS	\$-	\$-	\$-	\$-
ACLARIS	\$-	\$-	\$-	\$-
ACORDA THERAPEUTICS INC	\$-	\$-	\$-	\$-
AERIE	\$18,193.35	\$18,193.35	\$-	\$-
AKARX Inc	\$-	\$-	\$-	\$-
AKEBIA THERAPEUTICS INC	\$-	\$-	\$-	\$-
AKORN, INC	\$18,740.44	\$18,740.44	\$-	\$-
ALEXION PHARMACEUTICALS INC	\$-	\$-	\$-	\$-
ALFASIGMA USA	\$2,201.07	\$2,201.07	\$74.15	\$74.15
ALK ABELLO INC	\$-	\$-	\$-	\$-
ALKERMES INC	\$111,338.19	\$111,338.19	\$7,307.63	\$7,067.57
ALLEGIS	\$3,483.87	\$3,483.87	\$-	\$-
ALLERGAN PHARM	\$1,128,701.25	\$1,128,719.51	\$57,056.81	\$57,056.34
ALMATICA	\$4,691.16	\$4,691.16	\$-	\$-

Supplemental Rebate Agreements in Place during SFY 2021				
Manufacturer Name	Amount Plan Paid for Products During Contract Term	Amount Plan Paid to Pharmacies/ Providers for Products Under Contract During Contract Term	Total Supplemental Rebates Invoiced	Total Supplemental Rebates Collected
AMAG PHARMACEUTICALS, INC	\$74,023.66	\$74,023.66	\$25,117.84	\$25,117.84
AMARIN	\$34,245.19	\$34,245.19	\$-	\$-
AMGEN	\$974,677.15	\$974,677.15	\$123,949.18	\$123,708.92
AMNEAL PHARMACEUTICALS LLC	\$269,444.51	\$269,444.51	\$-	\$-
ANTARES PHARMA INC	\$8,441.87	\$8,441.87	\$-	\$-
AQUA PHARMACEUTICALS	\$-	\$-	\$-	\$-
ARBOR	\$56,480.20	\$56,480.20	\$-	\$-
ARKRAY USA INC	\$578.01	\$578.01	\$169.35	\$57.86
ASCEND THERAPEUTICS US, LLC	\$45,462.03	\$45,462.03	\$-	\$-
ASEGUA	\$320,640.00	\$320,640.00	\$51,200.00	\$51,200.00
ASSERTIO	\$55,907.89	\$55,907.89	\$-	\$-
ASTELLAS PHARMA US	\$24,660.70	\$24,660.70	\$-	\$-
ASTRA ZENECA	\$1,115,912.50	\$1,115,912.50	\$-	\$-
AVANIR PHARMACEUTICALS	\$628.79	\$628.79	\$-	\$-
AVEXIS	\$-	\$-	\$-	\$-
AVION PHARMACEUTICALS	\$7,237.37	\$7,237.37	\$-	\$-
BANNER LIFE SCIENCES	\$-	\$-	\$-	\$-
BAYER	\$401,352.34	\$401,352.34	\$-	\$-
BAYER DIAGNOSTICS	\$-	\$-	\$-	\$-
BECTON DICKINSON	\$107,335.98	\$107,335.98	\$6,352.63	\$5,775.27
BIODELIVERY SCIENCES INT	\$65,079.18	\$65,079.18	\$-	\$-
BIOGEN	\$57,351.91	\$57,351.91	\$827.60	\$827.60
BIOHAVEN PHARMACEUTICALS	\$82,309.55	\$82,309.55	\$-	\$-
BIOVENTUS LLC	\$-	\$-	\$-	\$-
BOEHRINGER INGELHEIM	\$1,181,101.19	\$1,181,101.19	\$3,555.20	\$4,330.65
BRISTOL-MYERS SQUIBB	\$1,251,089.29	\$1,251,089.29	\$31,100.60	\$30,661.36
CELGENE CORP	\$-	\$-	\$-	\$-

Supplemental Rebate Agreements in Place during SFY 2021				
Manufacturer Name	Amount Plan Paid for Products During Contract Term	Amount Plan Paid to Pharmacies/ Providers for Products Under Contract During Contract Term	Total Supplemental Rebates Invoiced	Total Supplemental Rebates Collected
CELLTRION	\$20.38	\$20.38	\$-	\$-
CEQR CORPORATION	\$-	\$-	\$-	\$-
CHIESI USA	\$-	\$-	\$-	\$-
CLOVIS ONCOLOGY INC	\$-	\$-	\$-	\$-
COHERUS BIOSCIENCES	\$-	\$-	\$-	\$-
COLLEGIUM PHARMACEUTICALS	\$35,671.96	\$35,671.96	\$-	\$-
COVIS PHARMA	\$2,264.57	\$2,264.57	\$-	\$-
CROWN LABORATORIES	\$54.84	\$54.84	\$-	\$-
CSL BEHRING LLC	\$11,353.97	\$11,353.97	\$-	\$-
CUMBERLAND PHARMACEUTICALS	\$972.22	\$972.22	\$-	\$-
CURRAX PHARMACEUTICALS LLC	\$-	\$-	\$-	\$-
CUTANEA LIFE SCIENCES INC	\$-	\$-	\$-	\$-
CYCLE PHARMACEUTICALS	\$467,860.85	\$467,860.85	\$-	\$-
DERMIRA, INC	\$-	\$-	\$-	\$-
DEXCOM	\$25,638.83	\$25,638.83	\$-	\$-
DIGESTIVE CARE	\$-	\$-	\$-	\$-
DUCHESNAY USA, INC	\$4,666.34	\$4,666.34	\$-	\$-
EGALET CORPORATION	\$-	\$-	\$-	\$-
EISAI INC	\$10,380.99	\$10,380.99	\$655.97	\$361.13
ELECTROCORE	\$-	\$-	\$-	\$-
ELI LILLY & COMPANY	\$2,578,314.60	\$2,578,361.47	\$229,336.24	\$229,166.92
EMD SERONO	\$175,317.38	\$175,317.38	\$-	\$-
EMERGENT DEVICES	\$41,498.72	\$41,498.72	\$3,948.75	\$3,948.75
ENCORE DERMATOLOGY, INC	\$-	\$-	\$-	\$-
ENDO PHARMACEUTICAL SOLUTIONS	\$33,412.42	\$33,412.42	\$-	\$-
EPI HEALTH LLC	\$376.36	\$376.36	\$-	\$-
ESPERION THERAPEUTICS	\$1,921.19	\$1,921.19	\$-	\$-
EXELIXIS INC	\$-	\$-	\$-	\$-

Supplemental Rebate Agreements in Place during SFY 2021				
Manufacturer Name	Amount Plan Paid for Products During Contract Term	Amount Plan Paid to Pharmacies/ Providers for Products Under Contract During Contract Term	Total Supplemental Rebates Invoiced	Total Supplemental Rebates Collected
EXELTIS USA DERMATOLOGY	\$117.88	\$117.88	\$-	\$-
EYEVANCE	\$531.13	\$531.13	\$-	\$-
FERRING	\$39,670.57	\$39,670.57	\$14,054.88	\$14,054.88
FIDIA PHARMA USA INC	\$-	\$-	\$-	\$-
FORTOVIA THERAPEUTICS	\$-	\$-	\$-	\$-
FORWARD SCIENCE	\$-	\$-	\$-	\$-
FOUGERA PHARMACEUTICALS INC	\$60,324.13	\$60,434.55	\$-	\$-
FRESENIUS USA	\$18,209.20	\$18,209.20	\$-	\$-
GALDERMA	\$12,400.20	\$12,400.20	\$-	\$-
GALEN	\$-	\$-	\$-	\$-
GENENTECH	\$559,588.79	\$559,588.79	\$-	\$-
GENESIS HEALTH TECHNOLOGIES	\$-	\$-	\$-	\$-
GILEAD SCIENCES INC	\$5,289,066.89	\$5,289,066.89	\$-	\$-
GLAXO SMITHKLINE	\$591,971.81	\$592,009.08	\$6,038.32	\$5,952.26
GLENMARK THERAPEUTICS INC	\$98,740.41	\$98,745.89	\$-	\$-
GREENWICH BIOSCIENCES	\$19,555.46	\$19,555.46	\$-	\$-
GREER LABORATORIES, INC	\$-	\$-	\$-	\$-
GRIFOLS USA, LLC	\$129,684.85	\$129,684.85	\$-	\$-
HELSINN THERAPEUTICS	\$-	\$-	\$-	\$-
HIKMA AMERICAS	\$151,206.85	\$151,228.80	\$-	\$-
HORIZON PHARMA USA, INC	\$250,818.40	\$250,818.40	\$-	\$-
HTL-STREFA	\$1,210.25	\$1,210.25	\$-	\$-
INDIVIOR	\$51,602.26	\$51,602.26	\$3,902.20	\$3,902.20
INSMED	\$-	\$-	\$-	\$-
INSULET	\$-	\$-	\$-	\$-
INSYS THERAPEUTICS, INC	\$-	\$-	\$-	\$-

Supplemental Rebate Agreements in Place during SFY 2021				
Manufacturer Name	Amount Plan Paid for Products During Contract Term	Amount Plan Paid to Pharmacies/ Providers for Products Under Contract During Contract Term	Total Supplemental Rebates Invoiced	Total Supplemental Rebates Collected
IPSEN BIOPHARMACEUTICALS INC	\$516.53	\$516.53	\$-	\$-
IRONSHORE	\$187.25	\$187.25	\$-	\$-
IRONWOOD PHARMACEUTICALS INC	\$-	\$-	\$-	\$-
JAZZ	\$-	\$-	\$-	\$-
JOHNSON and JOHNSON	\$1,679,094.67	\$1,679,094.67	\$12,733.58	\$12,656.95
JOURNEY MEDICAL	\$6,236.49	\$6,236.49	\$-	\$-
KALA PHARMACEUTICALS INC	\$704.10	\$704.10	\$-	\$-
KOWA PHARMACEUTICALS	\$4,925.82	\$4,925.82	\$-	\$-
KYOWA KIRIN	\$-	\$-	\$-	\$-
LEO PHARMA, INC	\$1,061.28	\$1,061.28	\$-	\$-
LIFESCAN	\$7,058.76	\$7,058.76	\$-	\$-
LUPIN PHARMACEUTICALS, INC	\$225,222.90	\$225,191.64	\$-	\$-
MAGNA PHARMACEUTICALS	\$-	\$-	\$-	\$-
MALLINCKRODT	\$41,663.69	\$41,663.69	\$-	\$-
MANNKIND CORPORATION	\$7,262.11	\$7,262.11	\$-	\$-
MAYNE PHARMA	\$24,624.46	\$24,624.46	\$-	\$-
MEDEXUS PHARMA	\$1,481.97	\$1,481.97	\$488.07	\$488.07
MELINTA THERAPEUTICS INC	\$6,257.61	\$6,257.61	\$-	\$-
MERCK & CO, INC	\$1,024,615.60	\$1,024,615.60	\$-	\$-
METUCHEN	\$-	\$-	\$-	\$-
MILLENNIUM PHARMACEUTICALS	\$-	\$-	\$-	\$-
MILLICENT	\$2,131.88	\$2,131.88	\$-	\$-
MINIMED DISTRIBUTION CORP	\$-	\$-	\$-	\$-
MISSION	\$480.92	\$480.92	\$-	\$-

Supplemental Rebate Agreements in Place during SFY 2021

Manufacturer Name	Amount Plan Paid for Products During Contract Term	Amount Plan Paid to Pharmacies/ Providers for Products Under Contract During Contract Term	Total Supplemental Rebates Invoiced	Total Supplemental Rebates Collected
MYLAN PHARMACEUTICALS INC	\$278,061.41	\$278,061.41	\$-	\$-
NABRIVA	\$-	\$-	\$-	\$-
NEOS THERAPEUTICS LP	\$8,052.16	\$8,052.16	\$-	\$-
NESTLE HEALTH SCIENCE	\$1,910.97	\$1,910.97	\$540.26	\$540.26
NEURELIS	\$3,205.44	\$3,205.44	\$-	\$-
NEUROCRINE BIOSCIENCES INC	\$162,833.03	\$162,833.03	\$-	\$-
NODEN PHARMA USA	\$-	\$-	\$-	\$-
NOVARTIS	\$1,170,466.58	\$1,170,471.45	\$7,045.61	\$5,428.29
NOVEN THERAPEUTICS LLC	\$13,023.47	\$13,023.47	\$2,402.06	\$2,402.06
NOVO NORDISK	\$2,076,506.11	\$2,076,543.41	\$89,552.37	\$91,439.38
OPKO PHARMACEUTICALS LLC	\$10,563.13	\$10,563.13	\$-	\$-
OPTINOSE US, INC	\$508.27	\$508.27	\$-	\$-
OREXO	\$2,654.83	\$2,654.83	\$-	\$-
ORTHOGENRX	\$-	\$-	\$-	\$-
OTSUKA	\$692,624.28	\$692,624.28	\$33,278.82	\$27,061.75
PARATEK PHARMACEUTICALS, INC	\$-	\$-	\$-	\$-
PARI RESPIRATORY	\$21.52	\$21.52	\$-	\$-
PERRIGO	\$6,914.32	\$6,914.32	\$-	\$-
PFIZER US PHARM	\$589,626.54	\$589,626.54	\$6,979.34	\$5,885.10
PHARMING HEALTHCARE INC	\$-	\$-	\$-	\$-
PIERRE FABRE PHARMA INC	\$-	\$-	\$-	\$-
PURDUE PHARMA	\$45,170.65	\$45,170.65	\$1,289.45	\$1,216.13
RADIUS HEALTH INC	\$25,620.35	\$25,620.35	\$534.21	\$534.21
RECKITT BENCKISER	\$12.52	\$12.52	\$2.12	\$2.12
REDHILL BIOPHARMA	\$9,471.90	\$9,471.90	\$-	\$-
REGENERON PHARMACEUTICALS INC	\$-	\$-	\$-	\$-

Supplemental Rebate Agreements in Place during SFY 2021				
Manufacturer Name	Amount Plan Paid for Products During Contract Term	Amount Plan Paid to Pharmacies/ Providers for Products Under Contract During Contract Term	Total Supplemental Rebates Invoiced	Total Supplemental Rebates Collected
RETROPHIN INC	\$-	\$-	\$-	\$-
RHODES PHARMACEUTICALS LP	\$35,086.51	\$35,086.51	\$-	\$-
ROCHE DIAGNOSTICS	\$2,075.86	\$2,075.86	\$81.15	\$49.50
SANDOZ INC	\$113,334.63	\$113,410.62	\$1,352.06	\$1,352.06
SANOFI - AVENTIS	\$609,130.90	\$609,199.77	\$20,885.27	\$12,595.43
SCILEX PHARMACEUTICALS INC	\$41,695.96	\$41,695.96	\$-	\$-
SEBELA PHARMACEUTICALS INC	\$-	\$-	\$-	\$-
SECURA BIO	\$-	\$-	\$-	\$-
SHIONOGI & COMPANY, INC	\$217.25	\$217.25	\$-	\$-
SHIRE-RICHWOOD	\$206,413.01	\$206,413.01	\$534.65	\$447.28
SK LIFE SCIENCE	\$-	\$-	\$-	\$-
SOBI INC	\$167,644.19	\$167,644.19	\$-	\$-
SUN PHARMA INDUSTRIES INC	\$118,823.56	\$118,823.56	\$-	\$-
SUNOVION	\$969,503.82	\$969,503.82	\$-	\$-
SUPERNUS PHARMACEUTICALS, INC	\$35,579.09	\$35,579.09	\$-	\$-
SYNERGY	\$-	\$-	\$-	\$-
TAKEDA	\$179,517.45	\$179,517.45	\$5,705.05	\$4,977.78
TERSERA THERAPEUTICS	\$3,407.60	\$3,407.60	\$-	\$-
TESARO, INC	\$-	\$-	\$-	\$-
TEVA	\$619,886.19	\$619,889.64	\$2,321.87	\$2,278.53
TherapeuticsMD INC	\$17,104.87	\$17,104.87	\$-	\$-
TOLMAR PHARMACEUTICALS INC	\$12,219.98	\$12,219.98	\$782.12	\$782.12
TRIS PHARMA	\$912.74	\$912.74	\$-	\$-
TRIVIDIA HEALTH	\$201,527.82	\$201,529.85	\$147,963.43	\$87,276.50
UCB INC	\$440,882.20	\$440,882.20	\$4,625.85	\$3,459.77
UNITED THERAPEUTICS CORP	\$-	\$-	\$-	\$-
UPSHER-SMITH	\$28,992.47	\$28,992.47	\$-	\$-

Supplemental Rebate Agreements in Place during SFY 2021

Manufacturer Name	Amount Plan Paid for Products During Contract Term	Amount Plan Paid to Pharmacies/ Providers for Products Under Contract During Contract Term	Total Supplemental Rebates Invoiced	Total Supplemental Rebates Collected
US WORLDMEDS, LLC	\$-	\$-	\$-	\$-
VALEANT PHARMACEUTICALS	\$-	\$-	\$-	\$-
VELOXIS PHARMACEUTICALS	\$-	\$-	\$-	\$-
VERTICAL PHARMACEUTICALS	\$-	\$-	\$-	\$-
VIFOR PHARMA, INC	\$-	\$-	\$-	\$-
VIVUS	\$553.09	\$553.09	\$-	\$-
VYERA PHARMACEUTICALS	\$-	\$-	\$-	\$-
VYNE PHARMACEUTICALS INC	\$4,154.46	\$4,154.46	\$-	\$-
WOMENS CHOICE PHARMACEUTICALS	\$-	\$-	\$-	\$-
XERIS	\$3,177.25	\$3,177.25	\$235.87	\$39.31
XSANVITA, LLC	\$-	\$-	\$-	\$-
ZEALAND PHARMA US INC	\$-	\$-	\$-	\$-
ZIMMER US, INC	\$-	\$-	\$-	\$-

Nevada Medicaid Fee-For-Service
Supplemental Rebate Agreement Report
State Fiscal Year 2021 (July 1, 2020 to June 30, 2021)
Data Provided by OptumRx

The overall drug rebate process follows the Omnibus Budget Reconciliation Act of 1990 (OBRA '90) as codified in Section 1927 of the Social Security Act (42 U.S.C. 1396r-8) and regulations promulgated by the Centers for Medicare & Medicaid Services (CMS). Under the Medicaid drug rebate program (MDRP), drug manufacturers must provide rebates to the federal government and states as a condition of having their drugs covered by Medicaid. The MDRP helps lower Medicaid prescription drug spending by ensuring that state Medicaid agencies receive discounts in the form of rebates on covered outpatient drugs. In order for their covered outpatient drugs to be covered and reimbursed by state Medicaid agencies, pharmaceutical manufacturers must enter into and have in effect the National Drug Rebate Agreement (NDRA) with the Secretary of the United States Department of Health and Human Services (HHS). The NDRA provides for the payment of Federal rebates by pharmaceutical manufacturers. Nevada Medicaid and the other state Medicaid Programs are third party beneficiaries of the NDRA's. The formulas for calculating the Federal unit rebate amount (URA) are set out by Federal statute.

States may also directly negotiate with manufacturers for voluntary supplemental rebates on top of federally required rebates. States may enter separate or supplemental drug rebate agreements as long as such agreements achieve drug rebates equal to or greater than the drug rebates set forth in the Secretary's national rebate agreement with drug manufacturers, which is published at 56 F.R. 7049 (1991).

The supplemental rebate does not reduce what is being paid under the NDRA but instead, provides an additional tool for states to help manage prescription drug spend. Pharmaceutical manufacturers enter into supplemental rebate agreements (SRA) with state Medicaid agencies to ensure preferred status on the states' Preferred Drug Lists.

The Nevada Medicaid Supplemental Drug Rebate Program (NMSDRP) has been in effect since January 1, 2012. The SRAs are between the manufacturers and the Nevada Department of Health and Human Services, Division of Health Care Financing and Policy (DHCFP). Generally, the SRAs are in effect for one calendar year beginning on January 1st and terminating on December 31st. In some instances, the SRA can have an alternative start date as a result of either newly contracted drugs or new NDCs (National Drug Codes) released for drugs currently under contract. Additionally, there are factors that may cause a contract to have a non-December 31st end date such as a product moving to non-preferred status or to coincide with planned Silver State Scripts Board (SSSB) review.

During State Fiscal Year 2021, the rebates negotiated under the NMSDRP only applied to Medicaid fee-for-service (FFS) utilization. The other entities, authorized under SB378 to participate in the Medicaid FFS PDL, did not elect to participate.

Supplemental rebates are calculated based upon two different types of calculations at the unit level:

- “Percentage of WAC” - set percentage of the drug’s published wholesale acquisition cost (WAC).
- “GNUP” (Guaranteed Net Unit Price) - WAC minus the Federal URA minus the GNUP.
 - In the event a drug’s WAC minus the Federal URA is lower than the GNUP, the supplemental rebate rate is zero.
 - Even though there are instances when the GNUP contract does not produce supplemental rebate savings, they remain in place to give Nevada Medicaid price protection in case the manufacturer raises the drug price during the contract term.

The type of calculation used for a particular product is defined within a manufacturer’s SRA with Nevada Medicaid.

Section F of the SRA provides confidentiality assurance that the State and the manufacturer agree to maintain confidentiality and to not disclose pricing information or pricing related terms and conditions.

Nevada Medicaid had 72 SRAs in place that were in effect during a portion of State Fiscal Year 2021 (July 1, 2020 – June 30, 2021) (hereinafter referred to as SFY 2021). Table 1 below summarizes the agreements:

Table 1 Row Definitions:

- Number of Contracts - The count of signed SRAs that were in force during some period within SFY 2021.
- Number of Unique Manufacturers Under Contract - The count of unique manufacturers with a signed SRA in force during some period within SFY 2021.
- Amount Medicaid Paid for Products During Contract Term - The amount Medicaid paid for all drugs subject to a manufacturer’s SRA during SFY 2021.
 - Example: Drug “A” was subject to an SRA from 01/01/2020 to 12/31/2020 but not under an agreement in 2021. This column would include the amount Medicaid paid to providers for Drug “A” for claims paid from 07/01/2020 to 12/31/2020.

- Amount Medicaid Paid to Pharmacies/Providers for Products Under Contract - The amount Medicaid paid to pharmacies and providers for drugs subject to a manufacturer's SRA during SFY 2021.
- Total Supplemental Rebates Invoiced - The supplemental rebate amount invoiced for SFY 2021 to manufacturers for drugs subject to SRAs.
- Total Supplemental Rebates Collected - The supplemental rebate amount collected for SFY 2021 to manufacturers for drugs subject to SRAs.
- Supplemental Rebate Percentage of Drug Spend for Contracted Products - The result of dividing the contract value by the drug spend for contracted drugs, expressed as a percentage.

Table 1

Summary of Supplemental Rebate Agreements in Place for SFY 2021	
Number of Contracts	72
Number of Unique Manufacturers Under Contract	37
Amount Medicaid Paid for Products During Contract Term	\$71,008,849.70
Amount Medicaid Paid to Pharmacies/ Providers for Products Under Contract During Contract Term	\$71,008,849.70
Total Supplemental Rebates Invoiced	\$9,899,735.91
Total Supplemental Rebates Collected	\$9,880,956.16
Supplemental Rebate Percentage of the Total Medicaid Paid for Contracted Products	13.9%

Table 2 below lists the SRAs in place during SFY 2021. The list is sorted alphabetically by manufacturer name and by SRA start dates.

Table 2 Column Definitions:

- Manufacturer Name - The name of the entity the State has contracted with in the SRA.
- Contract Term - The effective and termination dates of the SRA.

Table 2

Supplemental Rebate Agreements in Place for SFY 2021	
Manufacturer Name	Contract Term
ABBVIE US LLC	01/01/2020 - 12/31/2020
ABBVIE US LLC	01/01/2021 - 12/31/2021

Supplemental Rebate Agreements in Place for SFY 2021	
Manufacturer Name	Contract Term
AERIE PHARMACEUTICALS, INC.	01/01/2020 - 12/31/2020
AERIE PHARMACEUTICALS, INC.	01/01/2021 - 12/31/2021
ALKERMES, INC.	09/01/2020 - 12/31/2020
ALKERMES, INC.	01/01/2021 - 12/31/2021
ALLERGAN USA, INC.	01/01/2020 - 12/31/2020
ALLERGAN USA, INC.	01/01/2021 - 12/31/2021
ALLERGAN USA, INC.	04/01/2021 - 12/31/2021
AMGEN USA, INC.	01/01/2020 - 12/31/2020
AMGEN USA, INC.	01/01/2021 - 12/31/2021
ASEGUA THERAPEUTICS, LLC	01/01/2020 - 12/31/2020
ASEGUA THERAPEUTICS, LLC	01/01/2021 - 12/31/2021
ASTRAZENECA PHARMACEUTICALS LP	01/01/2020 - 12/31/2020
ASTRAZENECA PHARMACEUTICALS LP	01/01/2021 - 12/31/2021
BAYER HEALTHCARE, LLC	01/01/2020 - 12/31/2020
BAYER HEALTHCARE, LLC	01/01/2021 - 12/31/2021
BIOGEN IDEC U.S. CORPORATION	01/01/2020 - 12/31/2020
BIOGEN IDEC U.S. CORPORATION	01/01/2021 - 12/31/2021
BIOHAVEN PHARMACEUTICALS, INC.	04/01/2021 - 12/31/2021
BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.	01/01/2020 - 12/31/2020
BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.	01/01/2021 - 12/31/2021
BRISTOL-MYERS SQUIBB COMPANY	01/01/2020 - 12/31/2020
BRISTOL-MYERS SQUIBB COMPANY	01/01/2021 - 12/31/2021
CHIESI USA, INC.	01/01/2020 - 12/31/2020
CHIESI USA, INC.	01/01/2021 - 12/31/2021
DAIICHI SANKYO, INC.	01/01/2020 - 09/30/2020
DUCHESNAY USA	01/01/2020 - 12/31/2020
DUCHESNAY USA	01/01/2021 - 12/31/2021
EISAI INC	01/01/2020 - 12/31/2020
EISAI INC	01/01/2021 - 12/31/2021
ELI LILLY AND COMPANY	01/01/2020 - 12/31/2020
ELI LILLY AND COMPANY	09/01/2020 - 12/31/2020
ELI LILLY AND COMPANY	09/01/2020 - 03/31/2021
ELI LILLY AND COMPANY	01/01/2021 - 12/31/2021
ELI LILLY AND COMPANY	04/01/2021 - 12/31/2021
GENZYME CORPORATION	01/01/2020 - 12/31/2020
GENZYME CORPORATION	01/01/2021 - 12/31/2021
GILEAD SCIENCES, INC.	01/01/2020 - 12/31/2020
GILEAD SCIENCES, INC.	01/01/2021 - 12/31/2021
GLAXOSMITHKLINE LLC	01/01/2020 - 12/31/2020
INDEPENDENCE PHARMACEUTICALS, LLC	01/01/2020 - 12/31/2020
INDIVIOR INC.	01/01/2020 - 12/31/2020

Supplemental Rebate Agreements in Place for SFY 2021	
Manufacturer Name	Contract Term
INDIVIOR INC.	09/01/2020 - 12/31/2020
INDIVIOR INC.	01/01/2021 - 12/31/2021
JANSSEN PHARMACEUTICALS, INC.	09/01/2020 - 12/31/2020
JANSSEN PHARMACEUTICALS, INC.	01/01/2021 - 12/31/2021
NESTLE HEALTHCARE NUTRITION	05/01/2021 - 12/31/2021
NOVARTIS PHARMACEUTICALS CORPORATION	01/01/2020 - 12/31/2020
NOVARTIS PHARMACEUTICALS CORPORATION	01/01/2021 - 12/31/2021
NOVO NORDISK INC.	01/01/2020 - 12/31/2020
NOVO NORDISK INC.	01/01/2021 - 12/31/2021
OTSUKA AMERICA PHARMACEUTICAL, INC.	01/01/2020 - 12/31/2020
OTSUKA AMERICA PHARMACEUTICAL, INC.	09/01/2020 - 12/31/2020
OTSUKA AMERICA PHARMACEUTICAL, INC.	01/01/2021 - 12/31/2021
PARAPRO, LLC	01/01/2020 - 12/31/2020
PARAPRO, LLC	01/01/2021 - 12/31/2021
PARI RESPIRATORY EQUIPMENT, INC.	01/01/2020 - 12/31/2020
PARI RESPIRATORY EQUIPMENT, INC.	01/01/2021 - 12/31/2021
PFIZER INC	01/01/2020 - 12/31/2020
PFIZER INC	01/01/2021 - 12/31/2021
SANOFI-AVENTIS US LLC	01/01/2020 - 12/31/2020
SANOFI-AVENTIS US LLC	01/01/2021 - 12/31/2021
SHIRE US, INC.	01/01/2020 - 12/31/2020
SUNOVION PHARMACEUTICALS INC.	01/01/2020 - 12/31/2020
SUNOVION PHARMACEUTICALS INC.	01/01/2021 - 12/31/2021
TAKEDA PHARMACEUTICALS AMERICA, INC.	01/01/2021 - 12/31/2021
TEVA PHARMACEUTICALS USA, INC.	06/01/2020 - 03/31/2021
TEVA PHARMACEUTICALS USA, INC.	04/01/2021 - 12/31/2021
TRIS PHARMA	01/01/2020 - 12/31/2020
UCB, INC.	01/01/2020 - 12/31/2020
UCB, INC.	01/01/2021 - 12/31/2021

Table 3 below provides the values for supplemental rebates. Table 3 is sorted by Manufacturer Name.

Table 3 Column Definitions:

- Manufacturer Name - The name of the entity the State has contracted with in the SRA.
- Amount Medicaid Paid for Products During Contract Term - The amount Medicaid paid for all drugs subject to a manufacturer's SRA during SFY 2021.

- Example: Drug “A” was subject to an SRA from 01/01/2020 to 12/31/2020 but not under an agreement in 2021. This column would include the amount Medicaid paid to providers for Drug “A” for claims paid from 07/01/2020 to 12/31/2020.
- Amount Medicaid Paid to Pharmacies/Providers for Products Under Contract - The amount Medicaid paid to pharmacies and providers for drugs subject to a manufacturer’s SRA during SFY 2021.
- Total Supplemental Rebates Invoiced - The supplemental rebate amount invoiced for SFY 2021 to manufacturers for drugs subject to SRAs.
- Total Supplemental Rebates Collected - The supplemental rebate amount collected for SFY 2021 to manufacturers for drugs subject to SRAs.

Table 3

Supplemental Rebate Agreements in Place for SFY 2021				
Manufacturer Name	Amount Medicaid Paid for Products During Contract Term	Amount Medicaid Paid to Pharmacies/ Providers for Products Under Contract During Contract Term	Total Supplemental Rebates Invoiced	Total Supplemental Rebates Collected
ABBVIE US LLC	\$11,072,543.08	\$11,072,543.08	\$5,296,229.07	\$5,294,741.53
AERIE PHARMACEUTICALS, INC.	\$77,192.45	\$77,192.45	\$18,901.32	\$18,901.32
ALKERMES, INC.	\$761,426.38	\$761,426.38	\$79,493.42	\$162,910.84
ALLERGAN USA, INC.	\$4,484,684.34	\$4,484,684.34	\$168,847.09	\$168,848.64
AMGEN USA, INC.	\$2,975,859.29	\$2,975,859.29	\$37,360.38	\$37,360.38
ASEGUA THERAPEUTICS, LLC	\$889,057.68	\$889,057.68	\$123,539.27	\$123,537.27
ASTRAZENECA PHARMACEUTICALS LP	\$463,567.10	\$463,567.10	\$32,965.63	\$32,761.62
BAYER HEALTHCARE, LLC	\$0.00	\$0.00	\$0.00	\$0.00
BIOGEN IDEC U.S. CORPORATION	\$1,317,422.52	\$1,317,422.52	\$40,138.19	\$40,552.01
BIOHAVEN PHARMACEUTICALS, INC.	\$96,105.98	\$96,105.98	\$7,010.36	\$0.00
BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.	\$1,269,009.79	\$1,269,009.79	\$181,280.01	\$181,168.06
BRISTOL-MYERS SQUIBB COMPANY	\$2,628,671.63	\$2,628,671.63	\$0.00	\$0.00
CHIESI USA, INC.	\$51,597.46	\$51,597.46	\$12,371.52	\$12,371.52
DAIICHI SANKYO, INC.	\$12,326.36	\$12,326.36	\$3,094.60	\$3,094.60
DUCHESNAY USA	\$9,387.04	\$9,387.04	\$543.36	\$494.51
EISAI INC	\$321,745.21	\$321,745.21	\$35,445.52	\$35,445.57
ELI LILLY AND COMPANY	\$5,243,035.74	\$5,243,035.74	\$910,102.80	\$907,545.71

Supplemental Rebate Agreements in Place for SFY 2021

Manufacturer Name	Amount Medicaid Paid for Products During Contract Term	Amount Medicaid Paid to Pharmacies/ Providers for Products Under Contract During Contract Term	Total Supplemental Rebates Invoiced	Total Supplemental Rebates Collected
GENZYME CORPORATION	\$1,280,999.21	\$1,280,999.21	\$36,287.44	\$12,505.33
GILEAD SCIENCES, INC.	\$1,458,133.87	\$1,458,133.87	\$88,758.81	\$88,758.81
GLAXOSMITHKLINE LLC	\$180,383.93	\$180,383.93	\$4,073.48	\$4,073.70
INDEPENDENCE PHARMACEUTICALS, LLC	\$0.00	\$0.00	\$0.00	\$0.00
INDIVIOR INC.	\$1,895,134.48	\$1,895,134.48	\$288,238.80	\$287,875.32
JANSSEN PHARMACEUTICALS, INC.	\$7,408,890.38	\$7,408,890.38	\$221,367.70	\$221,367.73
NESTLE HEALTHCARE NUTRITION	\$4,707.83	\$4,707.83	\$368.59	\$0.00
NOVARTIS PHARMACEUTICALS CORPORATION	\$766,296.77	\$766,296.77	\$127,458.70	\$127,458.72
NOVO NORDISK INC.	\$2,127,448.09	\$2,127,448.09	\$519,775.23	\$519,769.13
OTSUKA AMERICA PHARMACEUTICAL, INC.	\$5,804,056.95	\$5,804,056.95	\$315,965.76	\$315,093.66
PARAPRO, LLC	\$822.54	\$822.54	\$243.61	\$243.61
PARI RESPIRATORY EQUIPMENT, INC.	\$9,020.34	\$9,020.34	\$180.72	\$242.59
PFIZER INC	\$3,440,681.42	\$3,440,681.42	\$737,899.47	\$737,899.41
SANOVI-AVENTIS US LLC	\$675,055.54	\$675,055.54	\$33,943.26	\$33,943.26
SHIRE US, INC.	\$801,484.86	\$801,484.86	\$59,827.40	\$59,827.42
SUNOVION PHARMACEUTICALS INC.	\$7,970,156.59	\$7,970,156.59	\$373,944.97	\$364,054.90
TAKEDA PHARMACEUTICALS AMERICA, INC.	\$835,470.46	\$835,470.46	\$27,190.57	\$27,191.97
TEVA PHARMACEUTICALS USA, INC.	\$167,288.39	\$167,288.39	\$12,795.57	\$10,180.90
TRIS PHARMA	\$105,160.11	\$105,160.11	\$18,076.16	\$18,065.83
UCB, INC.	\$4,404,025.89	\$4,404,025.89	\$86,017.13	\$32,670.29